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Abstract 
SYNTHETIC, SULFATED, LIGNIN-BASED ANTICOAGULANTS 
by Akul Yugesh Mehta, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2014. 
Supervisor: Umesh R Desai 
Chemoenzymatically synthesized low molecular weight lignin polymers have been previously 
found to be potent inhibitors of a number of serine proteases via allosteric mechanisms targeting 
heparin binding sites. Herein, we describe the creation of synthetic sulfated β-O4 lignin (SbO4L) 
polymer, which is more homogenous compared to previous lignins with respect to its inter-
monomeric linkage. SbO4L is a selective inhibitor of thrombin and plasmin. SbO4L was found 
to act via a unique mechanism targeting thrombin exosite 2 in a manner similar to platelet 
glycoprotein Ibα (GPIbα). Advanced hemostasis and thrombosis assays demonstrated that 
SbO4L acts via a dual mechanism: as an anticoagulant, by allosteric inhibition of thrombin 
catalysis; and as an antiplatelet agent, by competing with platelet GPIbα. These mechanisms are 
comparable in potency to low molecular weight heparins currently used in the market, indicating 
that targeting exosite 2 may yield clinically useful drugs in the future. Since the β-O4 type lignin 
was found to be selective for thrombin and plasmin, we hypothesized that other scaffolds from 
lignins could be potent inhibitors of other serine proteases. In particular, we screened a library of 
xix 
 
synthetic sulfated small molecules against factor XIa – an emerging target for prophylactic 
anticoagulation. Our search identified a sulfated benzofuran trimer (a mimic of β-5 type linkage 
found in lignins) as a potent inhibitor of factor XIa. Surprisingly, this inhibitor did not compete 
with heparin. A plausible binding site in the A3 domain of factor XIa was proposed by using 
molecular modeling techniques. The binding pose demonstrated good correlation with the 
structure activity data from in vitro studies. Further confirmation that the apple domains were 
required was proved by testing the trimer against recombinant catalytic domain. A 40-fold 
decrease in activity was observed. A temperature-dependant perrin plot demonstrated that factor 
XIa undergoes a large conformational change in the presence of the trimer, which is possibly 
converting the enzyme back into the zymogen-like shape. In general, the synthetic sulfated 
lignins can act as a useful foundation to develop anticoagulant, antiplatelet, and anti-
inflammatory molecules in the future. 
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Chapter 1: Introduction 
1.1 Blood, Coagulation and Hemostasis 
Blood is an essential body fluid that helps transport nutrients to all cells of the body, 
while simultaneously transporting metabolic waste products away from the cells for excretion.
1
 
An average human being contains almost 4 liters of blood within the body. Part of this is made 
up of proteins, which float in the liquid fraction of blood called plasma and are essential for 
coagulation and transportation of nutrients. The other part of blood is composed of cells. Three 
major types of cells make up the cellular composition of blood, namely: (a) Red blood cells 
(erythrocytes) – essential for carrying oxygen to various tissues of the body. (b) White blood 
cells (leucocytes) – essential for fighting infections and performing various protective functions. 
(c) Platelets (thrombocytes) – essential for prevention of blood loss.1  
In toto, these components of blood help perform a variety of functions such as supplying 
nutrients and oxygen to various parts of the body; transporting waste products from various 
tissues to the kidneys; lungs and liver for metabolism and excretion; protecting the body from 
various infections; maintaining body pH, hydration and temperature; and coagulation in case of 
injury. Thus, proper blood flow within the body is essential to maintain the homeostatic balance 
of the body.
1
 
To maintain appropriate blood flow conditions, procoagulant and anticoagulant factors 
are present within the blood.
2
 In case of injury, excessive blood loss is prevented by the 
2 
 
procoagulant factors, which result in hemostasis. Simultaneously, anticoagulant factors help 
maintain proper blood flow within the rest of the body. This balance of procoagulant and 
anticoagulant factors is maintained by certain proteins and regulatory factors present in the blood 
by a process known as the coagulation cascade, along with the platelet cells of the blood.
2
 
 1.2 The Coagulation Cascade 
The coagulation cascade is composed of several proteins which are freely floating within 
the blood in their inactive state or zymogen form (Figure 1). Upon injury or under pathological 
conditions, these zymogens are activated in a sequential step by step manner via either the 
intrinsic pathway (contact activation pathway) or the extrinsic pathway (tissue factor pathway).  
 
Figure 1. The coagulation cascade of blood. In black are the procoagulant factors, while in grey 
are the anticoagulant pathways. Thrombin (factor IIa) plays a key role in the cascade. It 
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catalyzes the conversion of soluble fibrinogen to insoluble fibrin which eventually leads to clot 
formation by thrombin activated fXIIIa. It acts as a link between the cascade and platelets for 
aggregation via binding to glycoprotein Ibα (GPIbα). It provides positive feedback to the cacade 
by activating fXI, fVIII and fV, while also providing negative feedback in presence of 
thrombomodulin via protein C pathway. Thrombin activity can be regulated by serpin-GAG 
complexes. Image adapted from reference 3.
3
 
 
In case of injury, there is damage to the endothelium which exposes the subendothelial 
tissues (mainly composed of smooth muscle cells). These subendothelial cells express tissue 
factor (TF) on their surface, which acts as a receptor for factor VII in turn activating it to form 
factor VIIa.
4,5
 The TF-VIIa complex forms the extrinsic tenase complex which is capable of 
activating factor X of the common pathway.
6
 On the other hand, the intrinsic pathway of 
coagulation is a means of amplification of clot formation. It is activated when collagen (or other 
anionic substances such as dextran sulfate) is exposed and forms a complex with high-molecular 
weight kininogen (HMWK), prekallikrein and factor XII.
7
 Upon formation of this complex, 
prekallikrein is activated to kallikrein and factor XII gets activated to form factor XIIa. Factor 
XIIa in turn catalyzes the activation of factor XI to factor XIa, which subsequently activates 
factor IX to factor IXa. Factor IXa is then capable of activating factor X of the common 
pathway.
8
 
The sequential activation via either of the pathways leads to the activation of factor X to 
factor Xa from where the final common pathway initiates. Factor Xa catalyzes the conversion of 
prothrombin (factor II) to thrombin (factor IIa). Thrombin has a large array of functions within 
the cascade (Figure 1): (a) its primary role is to catalyze the conversion of soluble fibrinogen to 
4 
 
insoluble fibrin which ultimately leads to a “clot” that can plug the site of bleeding or damage;9 
(b) it also activates factor XIII to factor XIIIa, which helps in cross-linking of the fibrin and 
hence strengthens the clot;
9
 (c) it provides positive feedback to the coagulation cascade by 
activating factors VIII,
10
 and factor V,
11
 which can dramatically propagate the clot formation by 
forming the  tenase and prothrombinase complexes with factor IXa and factor Xa, respectively; 
(d) it can itself activate factor XI to factor XIa further providing positive feedback to the 
cascade;
12
 (e) it can even activate platelets by binding to platelet glycoprotein Ibα (GPIbα) which 
can help in platelet plug formation via activation and aggregation;
13
 (f) and lastly, thrombin also 
plays a subtle anticoagulant role in the presence of thrombomodulin by activation of protein C, 
which is capable of degrading factor VIIIa and factor Va, and has anti-inflammatory actions.
14,15
  
The fibrin clot thus formed, along with the aggregated platelets forms a thrombus, which 
helps in checking the blood loss and begin the wound healing process. Anticoagulant factors 
such as heparin along with the serine protease inhibitors (serpins), antithrombin and heparin co-
factor II, help maintain proper blood flow within the circulatory system away from the site of 
thrombus formation.
16
 Furthermore, fibrinolytic pathways involving plasmin can help break 
down already present clots within the body to restore normal blood flow once healing has 
completed.
17
  
 
1.3 The Platelets 
Hematopoietic stem cells present within the bone marrow form the highly specialized 
megakaryocyte cells, which function to produce and release platelets into the circulation.
18
 
Platelets are anuclear, discoid shaped cells, which range from 1-3 μm in diameter and 0.5 μm in 
5 
 
thickness and are the smallest cells found in the circulation.
19,20
 Blood vessel walls are lined with 
a layer of endothelial cells, which play important physiological roles and participate directly in 
hemostasis by interaction with blood components (Figure 2). They are also believed to be the 
building blocks of vessels.
21
 The endothelial cells release nitric oxide and prostacyclin, which 
help keep the platelets in their inactive state.  
Underlying the layer of endothelial cells is a basement membrane. Below the membrane 
is a layer of collagen matrix and smooth muscle cells. The basement membrane 
(subendothelium) underlying the endothelium produces collagen on the surface. Platelets bind to 
the collagen via a cell adhesion protein called the von Willebrand factor (vWF), which is present 
in the blood (Figure 2). Thus, under physiological conditions collagen is not exposed to the 
blood stream where platelets are present. However, upon injury, collagen its exposed to the 
blood stream and can activate the platelets with the help of vWF present in the blood.
22
  
Upon activation, platelets release alpha granules and dense granules which in turn 
activate other platelets generating a chain reaction (Figure 2). The components from these 
granules, such as ADP and thromboxane-2 (TXA-2) help in adhesion and aggregation of 
platelets, and are also procoagulant and repairing in nature.
23
 Asprin, which is an antiplatelet 
drug, targets the biosynthesis of TXA-2 to provide antiplatelet effects. Activation of platelets 
also exposes phophatidylserine on the platelet surface, which activates factor Xa to enhance 
thrombin generation and propagate the coagulation cascade to form a fibrin mesh.
24
 The unique 
character demonstrated by activated platelets is that they undergo a dramatic shape-change, 
producing pseudopods from their surface and obtaining a more stellate shape. Platelet shape 
change is a complex process, which is controlled by proteins that regulate actin architecture.
25
 
Such a platelet is then able to clump with other platelets to form the platelet plug.  
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Figure 2. The role of platelets during injury. From left to right: During normal blood flow, 
endothelial cells keep the platelets at rest by releasing nitric oxide (NO) and prostacyclin (PGI2). 
The endothelial cells also act as a barrier preventing von Willebrand factor from interacting 
with collagen. During injury, the endothelial layer is disrupted exposing the collagen to the Von 
Willebrand factor. Binding of VWF to collagen provides a surface for interaction of platelet 
surface integrins and glycoprotein Ibα. This causes the platelets to roll on the vessel wall and be 
captured via stable adhesion even under flow. Interaction of collagen with GPVI stimulates the 
spreading of the platelet and activation, which in turn releases feedback agonists ADP and 
thromboxane-2 (TXA-2) causing recruitment of more platelets for activation. Furthermore, 
activation of platelets exposes phosphatidylserine on platelet surface which provides a 
procoagulant surface for thrombin activation. Together, aggregation of activated platelets and 
thrombin mediated fibrin mesh formation lead to formation of platelet plug. 
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Platelets mediate a number of vascular and cellular responses via a number of receptors.
26,27
 
Since both coagulant factors and platelets assist in hemostasis, there is significant cross-talk 
between the two systems via platelet receptors. The platelet receptors mainly involved in such 
inter-play include:  
1. Glycoprotein Ibα (GPIbα) - which is known to interact with thrombin, vWF and other 
coagulation factors such as factor XI, XII, VIIa and kininogen. 
2. Protease activated receptors PAR1, PAR3 and PAR4 – which are known receptors for 
thrombin and are activated by thrombin. 
3. Integrins like αIIbβ3 – which are known to bind with fibrinogen and vWF for adhesion. 
Of these reactions, the GPIbα-thrombin reaction is critical for platelet-coagulation inter-play. 
GPIbα is one of the most abundant surface receptors on platelets and thrombin is a versatile 
catalytic enzyme. In fact, thrombin bound to GPIbα shows an increased catalytic ability towards 
PAR activation suggesting that physiologically this complex might play a crucial role in 
recruiting platelets during hemostasis induced by the coagulation system.  
 
1.4 Structure of Thrombin 
Thrombin is a ~36,000 Da globular enzyme which is formed from its precursor 
prothrombin via cleavage of two peptide bonds, i.e., R320-I321 and R272-T273 (prothrombin 
numbering).
28-32
 Upon activation thrombin is composed of an amino terminal light chain (“A” 
chain ~6,000 Da) and a carboxy terminal heavy chain (“B” chain ~31,000 Da).30 The two chains 
are covalently linked via single disulfide bond.
32
 Structurally, thrombin contains an active site 
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with a catalytic triad, a sodium binding site and two allosteric electropositive sites called exosite 
1 and exosite 2 (Figure 3). 
 
Figure 3. The structure of human thrombin, showing the presence of a Ser195 at the active site 
catalytic triad, a sodium binding site located close by, and two electropositive allosteric sites 
called exosite 1 and exosite 2. 
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Catalytic Triad and Mechanism 
Thrombin is a serine protease. A specific serine residue (Ser195) within the active site is 
essential for its protein cleaving catalytic activity (Figure 4A).
33
 This serine residue is a part of a 
catalytic triad composed of Ser195, His57 and Asp102 (chymotrypsin numbering), which is 
involved in a “ping-pong” catalysis involving the substrate and water (Figure 4B).34 The 
hydroxyl group on the serine (seroxide) acts as a nucleophile and attacks the carbonyl carbon of 
the peptide substrate to form a tetrahedral intermediate. To enhance this nucleophilicity of the 
Ser195, the His57 lone pair on N3 or Nε of the imidazole ring is capable of accepting the 
hydrogen of the hydroxyl of the Ser195. The Asp102 carboxylate hydrogen bonds with the other 
imino group (N1 or Nδ) on the histidine imidazole to further catalyze the formation of the 
tetrahedral intermediate. The nitrogen-carbon bond within the substrate finally breaks as the 
peptide nitrogen accepts the hydrogen from the histidine to release the amine fragment of the 
substrate (C-terminus). The carbonyl part of the substrate in turn forms a covalently linked acyl-
enzyme intermediate. At this moment, water comes into the reaction to re-protonate the His57, 
while the hydroxyl moiety attacks the carbonyl carbon of the acyl-enzyme intermediate to form 
another tetrahedral intermediate. In the final step, the protonated His57 is capable of regenerating 
the Ser195 hydroxyl while the tetrahedral intermediate structure breaks down to release the 
carboxylate part of the substrate (N-terminus). 
10 
 
 
Figure 4. Serine Protease Catalysis (A) Catalytic triad as observed in thrombin consisting of 
Ser195, His57 and Asp102. (B) Mechanism of catalytic-triad mediated peptide bond cleavage in 
serine proteases. 
A
B
11 
 
Active Site Structure 
Like other proteases, the active site of thrombin can be represented by the Schechter and 
Berger nomenclature (Figure 5A).
35
 According to this nomenclature, the active site of a protease 
is composed of subsites (S), wherein the sites on the enzyme which bind the substrate outwards 
from the site of cleavage towards the amino-terminus of the substrate are numbered S1, S2, 
S3,…Sn; while the sites on the enzyme which bind the substrate outwards from the site of 
cleavage towards the carboxy-terminus of the substrate are numbered S1’, S2’, S3’,….Sn’. 
Thrombin contains an acidic Asp189 residue at the bottom of the S1 pocket, which further 
classifies it into the trypsin family of serine proteases (Figure 5C). However, unlike trypsin, 
thrombin is highly selective in cleaving between Arg/Lys-Gly bonds. In fact, thrombin is 
selectively able to cleave two specific Arg-Gly bonds out of 181 Arg/Lys-Xaa possible bonds on 
fibrinogen to produce fibrin.
36
 The thrombin S1 pocket can possibly accommodate more bulkier 
P1 groups than trypsin.
37
 Above the S1 pocket is a Trp215 residue, which forms a hydrophobic 
base for the S2 and S4 binding pockets (Figure 5C). The active site of thrombin forms a 
particularly deep cleft due to the insertion 60-loop above and the γ-loop (also called the autolysis 
loop) below. The 60-loop helps form the S2 and S4 sites, while the γ-loop forms the S’ side 
(Figure 5B). These loops help enhance thrombin specificity for substrates.
38
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Figure 5. The active site of thrombin. (A) A structural depiction of the Schechter and Berger 
nomenclature of serine protease active site pockets (depicted as S3, S2, S1, S1’, S2’ and S3’ on 
60-Loop
-Loop
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B
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the enzyme) in relation to the protein substrate residues (depicted as P3, P2, P1, P1’, P2’ and 
P3’). (B) A surface model of thrombin showing the different pockets of the active site with the 
Ser195 of the catalytic triad in red. (C) The underlying chain structure and the defining amino 
acid residues of the corresponding active site pockets. 
 
 
The Sodium Binding Site 
Located approximately 15 Å from the catalytic triad is a Na
+
 binding site formed by three 
antiparallel β-strands of the B-chain (Met180-Tyr184a, Lys224-Tyr228, and Val213-Gly219) 
and diagonally crossed by the Glu188-192 strand (Figure 6). The binding of sodium at this site is 
highly selective over other monovalent cations like K
+
, Li
+
 or even Rb
+
. This Na
+
 is coordinated 
to the main chain oxygens of Arg221a, Lys224 and four conserved water molecules. The binding 
of Na
+
 forms a water mediated hydrogen bond with the Asp189 residue, which forms the base of 
the S1 pocket and forms a charge-relay system with the catalytic triad. This binding therefore, 
shifts thrombin from a “slow” to “fast” form. In fact, the binding of other ions like K+ in place of 
Na
+
, shifts thrombin to an inactive or slow form.
39
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Figure 6. Structural difference due to sodium binding relays into the catalytic triad. An overlay 
of the fast sodium-bound form of thrombin (protein chain in blue, sodium as yellow ball, and 
waters as red balls) and the slow sodium-free form of thrombin (protein chain in yellow, waters 
as green balls) highlights the presence of a water mediated switch which links the sodium to the 
catalytic triad of thrombin. Image is taken from reference 40.
40
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Exosite 1 
Located approximately around 20 Å away from the active-site catalytic triad, there is a 
surface depression, which starts at the end of the P’ site of the enzyme. This surface depression is 
mainly formed by insertion loops from 70-80 and is known as exosite 1 (Figure 7). Exosite 1 also 
encompasses some bordering residues from the 37 loop and Lys109, Lys110 residues. Exosite 1 
is electropositive in nature due to the presence of Lys36, Lys70, Lys81, Lys107, Lys109, and 
Lys110; and Arg35, Arg67, Arg73, Arg75, Arg77A.
32
 The base of the exosite 1 is however 
hydrophobic and is formed by the side chains of Tyr76 and Ile82. Exosite 1 is known to be 
crucial for fibrinogen activation by thrombin.
32,41
 It is also known to interact with PARs,
42
 fV,
43
 
fVIII,
44
 fXI,
45
 HCII,
46
 hirudin,
47
 and thrombomodulin.
48
  
 
Exosite 2 
Exosite 2 is a large, highly electropositive area located near the C-terminus of the heavy 
chain of thrombin. As it binds heparin, this exosite is also known as the heparin binding exosite 2 
and is roughly 200 Å
2
 in area (Figure 8). The electropositive residues within exosite 2 include: 
Arg93, Arg97, Arg101, Arg126, Arg165, Lys169, Arg173, Arg175, Arg233, Lys235, Lys236 
and Lys240.
32,49
 As most of these residues do not have a compensatory acidic residues, exosite 2 
presents a highly electropositive surface, which can attract anionic molecules such as heparin. In 
the zymogen form, the exosite 2 is covered by the F2 domain and is inaccessible in prothrombin, 
pre-thrombin-1 and meizothrombin forms.
50,51
  
Besides heparin, exosite 2 is known to interact with platelet receptor GPIbα,52 
prothrombin fragments 1.2,
50
 chondroitin sulfate moiety of thrombomodulin,
53
 and fVIII.
44
 Some 
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exogenous ligands such as haemadin from Haemadipsa sylvestris leech is also known to interact 
with thrombin exosite 2.
54
 Additionally, aptamers have been synthesized to interact with exosite 
2 via their polyanionic nature.
55,56
 
 
Figure 7. Structure of human thrombin showing all electropositive residues (arginines and 
lysines) present on the exosite 1 (in yellow). 
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Figure 8. Structure of human thrombin showing all electropositive residues (arginines and 
lysines) present on the exosite 2 (in green). 
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 1.5 Thrombin Allostery  
Allostery by definition is the phenomenon where a ligand binding at a site away from the 
orthosteric/active site can affect the activity of the protein/enzyme. Thrombin is a highly plastic 
enzyme.
57
 Its structural conformations and activity is highly regulated by the ligands it binds 
within the blood. The three aforementioned sites, i.e., the sodium binding site, and the exosites 1 
and 2, present extended surfaces away from the active site via which ligand binding can 
demonstrate allosterism. 
1.5.1. Sodium Binding Site and Thrombin Allostery 
Binding of Na
+
 ions to thrombin has been shown to increase thrombin activity for well 
over thirty years.
58
 However, since the lack of Na
+
 did not completely abolish activity, it was 
concluded that Na
+
 is a positive allosteric effector of thrombin rather than a cofactor. Instead, 
Na
+
 binding to thrombin has been shown to shift the enzyme from “slow” or low-activity form, 
to a “fast” or high-activity form towards substrate hydrolysis.40 Moreover, it has also been shown 
that the substrate specificity of these two forms of thrombin is widely different. The slow-form 
of thrombin has been shown to be a stronger anticoagulant enzyme with greater activation of 
protein C by binding to thrombomodulin and lack of activity against fibrinogen, PAR-1 and 
other procoagulant factors. On the other hand, the fast Na
+
-bound form of thrombin demonstrates 
higher procoagulant activity as a result of greater proteolytic activity towards fibrinogen, PAR-1 
and other procoagulant factors.
59,60
 A structural link has been established between the Na
+
-
binding site and the catalytic triad which shows that a hydrogen bond network links the Na
+
 ion 
to the Asp189 of the active site.
61
  Such an interaction could possibly account for the change in 
activity and substrate specificity. If K
+
 is replaced in place of Na
+ 
in the buffer, the enzyme shifts 
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to a more inactive or slow form.
39
 This demonstrates the selectivity for, and the fine tuning by 
Na
+
 at this site to maintain thrombin procoagulant activity and raises the possibility that this site 
could be a switch to shift between allosteric forms. 
1.5.2. Exosite 1 and Thrombin Allostery 
Binding of different ligands to exosite 1 induces differential substrate specificity and 
activity within the active site. For example, thrombomodulin binding at exosite 1 changes 
thrombin substrate specificity from fibrinogen cleavage to protein C activation.
62,63
 On the other 
hand, hirugen binding mildly alters (either increases or decreases) catalytic efficiency of 
thrombin towards an array of small chromogenic substrates and fibrinogen.
64
 A PAR receptor 
fragment has been shown to resemble hirudin and alter thrombin specificity towards 
chromogenic substrates.
65
 When bound to the exosite 1 of thrombin, PAR receptor fragments 
also show a collapsed conformational change within the active site via a network of polar 
interactions.
66
 A 15-nucleotide DNA aptamer (also called HD1 or TBA15) was found to bind to 
thrombin exosite 1 causing inhibition of fibrinogen-clotting, platelet activation, and 
thrombomodulin-dependent protein C activation.
67-69
  Several studies have also pointed towards 
an allosteric link between exosite 1, the Na
+
 binding site and the active site, suggesting a strong 
interplay among these sites.
47,70,71
  
1.5.3. Exosite 2 and Thrombin Allostery 
Thrombin exosite 2 is more electropositive compared to exosite 1, and hence it is known 
to bind more anionic ligands like heparin. Although heparin binding does not induce allosteric 
modification of enzyme structure or function, it plays a vital role in a bridging mechanism for 
acceleration of inactivation by antithrombin III.
49,72
 Binding of anionic proteins/peptides has 
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shown allosteric redirection or inhibition of the protease activity of thrombin. For example, the 
binding of the activation peptide fragment 1.2 (F12) from prothrombin to exosite 2 of thrombin 
results in the conversion of the enzyme to a zymogen like inactive state. The study also proposes 
a link between exosite 2 and the sodium binding site.
73
 The fibrinogen γ’ chain is also known to 
bind thrombin exosite 2 which results in inhibition of the proteolytic activity towards 
proteinaceous substrates, possibly resulting from perturbation of the Na
+
 binding site, exosite 1 
and the active site.
74-76
 Another DNA aptamer (DNA 60-18[29] or HD22), that is 29-nucleotides 
in length was identified, which binds exosite 2 of thrombin and inhibits fibrin clot formation.
77
  
On the flip-side, ecotin, an E. coli derived protein, decreases inhibition of thrombin by 
heparin/antithrombin, and produces a two-fold increase in thrombin catalysis of fibrinogen 
cleavage and inhibits thrombin-induced platelet aggregation via binding to exosite 2.
78
 Platelet 
GPIbα was also found to bind at exosite 2 and inhibit thrombin’s fibrin formation ability as well 
as activity towards other coagulation proteins, but it activates thrombin towards PAR activation, 
thereby redirecting thrombin towards a pro-thrombotic role.
79-82
 More recently, a novel sulfated 
pyranosic (13)-β-L-arabinan (Ab1), which is obtained from the green seaweed Codium 
vermilara (Byropsidales) was found to inhibit thrombin via direct and indirect mechanisms by 
binding to an allosteric site and inducing a conformational change.
83
 However, more evidence 
needs to be presented to confirm that it does bind to exosite 2, since the authors have only 
performed molecular dynamic simulations to propose the binding at this site.  
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1.5.4. Link between Allosteric Sites 
There exists some evidence that there is an allosteric network within thrombin, wherein 
ligand binding at either exosite would affect other allosteric sites such as the other exosite, the 
Na
+
 binding site or the active site. We have seen several examples above which demonstrate a 
link between the exosites and the active site and the Na
+
 binding site. It is therefore feasible that 
the two exosites could also be linked.  
A study in 1997 was the first to demonstrate any kind of link between the two exosites.
84
 
A more recent study involving several exosite ligands such as, HD1, HD22, γ’-peptide, heparin, 
γA/γA-fibrin/fibrinogen, and prothrombin fragment 2 (FP12), has shown that there is long range, 
allosteric, bidirectional communication between the exosites 1 and 2 of thrombin.
85
 A 
contradictory study involving mutagenesis gave some evidence that exosite 2 is an independent 
ligand binding site, but there is a link between the exosite 1 and the Na
+
 binding site and the 
active site.
62
 In comparison to the studies linking the two exosites using covalent fluorescent 
labels and surface-bound proteins in SPR, this study involved highly unnatural thrombin mutants 
with loops stabilized by engineered disulfide bonds within exosite 1 and the Na
+
 binding site.  
Hence, interpretation of either of the results may be skewed due to experimental conditions, and 
care should be taken in not concluding possibilities or impossibilities about a link existing 
between the two exosites in a natural wild-type thrombin. 
The occurrence of thrombin in such a vast variety of activity states due to various ligand 
binding, has led to a newer “ensemble view of thrombin allostery”, wherein thrombin can exist 
in various activation states in equilibrium and depending upon the ligands that bind to it a certain 
state may predominate over others.
86
 Thus thrombin can be thought of as a “Swiss Army Knife” 
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within the coagulation cascade, which can be used and directed to a variety of utilities depending 
on the body’s needs by various “hands” (or ligands). It also offers the development of newer 
ligands to redirect this knife into the safest possible direction and use it more for benefit than 
harm. 
 
 1.6 Sulfated Tyrosine Containing Proteins Involved in Hemostasis 
Tyrosine sulfates were first detected in 1984.
87
 Yet even 30 years later, there is little 
known about the action of this post translational modification. From an evolutionary point of 
view, sulfation of tyrosines is a post translational modification, which is even found in plants. In 
humans (and mammals), sulfated tyrosine containing proteins are present mainly in the 
cardiovascular system, and especially in the blood.
88
 However, little is known about the function 
of these groups within these proteins. Sulfated tyrosines are quickly gaining importance as a 
novel post translational modification, and people are realizing sulfated-tyrosine binding sites 
could possibly be targeted to obtain highly specific and allosteric drugs.  
Tyrosine sulfation is carried out by tyrosylprotein sulfotransferase (TPST) enzyme. There 
are two isoforms of this enzyme, TPST-1 and TPST-2. Both TPST-1 and TPST-2 are found 
throughout the body at varying expression levels and use 3′-phosphoadenosine 5′-phosphosulfate 
(PAPS) as a sulfate donor (Figure 9).
89,90
 It is of interest that the specificity of these enzymes to 
catalyze tyrosine sulfation is also different. Hence the expression of these enzymes seems to 
control important physiological outcomes. In fact, shear stress is known to play a role in the 
expression levels of these enzymes within endothelial cells, thereby further implicating the role 
of protein tyrosine sulfation in blood vessel pathologies.
91
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Figure 9. Tyrosine sulfation reaction as catalyzed by tyrosylprotein sulfotransferase (TPST) 
enzymes in the presence of 3′-phosphoadenosine 5′-phosphosulfate (PAPS).  
 
Sulfated tyrosines are often located adjacent to negatively charged groups such as 
aspartates and glutamates. These sulfated tyrosine rich anionic peptides (STRAPs) are present in 
proteins that are essential for cell adhesion, immune response, and coagulation.
88,90,92
 These 
STRAPs could provide selective interactions as there are no sequences in the literature, which 
were absolutely identical. This implies that these interactions are highly specific for certain 
characteristic features and mimicking them could provide a useful approach for drug design and 
development.  
There are additional proteins found apart from those in the blood, which also contain 
sulfated tyrosines, such as gastrointestinal hormones (gastrin/CCK family), certain digestive 
enzymes, growth and developmental hormones and neuroendocrine peptides. 
88,90,92
 Yet no 
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STRAP is absolutely identical, further implying that mimicking STRAPs could provide useful 
therapies in not just hemostatic disorders but also inflammatory, neuronal, gastrointestinal and 
developmental disorders. 
 
1.7 Structure and Functions of GPIbα 
Glycoprotein Ibα (GPIbα) is a 626 amino acid (Uniprot ID: P07359) long surface 
glycoprotein present on platelets. GPIbα exists as a complex along with GPIbβ, GPIX and GPV 
to form the GPIb-IX-V complex (Figure 10).
93,94
 The long chain of GPIbα is split into 4 regions: 
N-terminal ligand binding domain (1-282), sialomucin core domain which acts as a linker, a 
transmembrane domain (506-526), and a cytoplasmic tail.  
The N-terminal ligand binding domain is the business end of the protein that is 
extracellular and interacts with several ligands. It consists of an N-terminus capping sequence (1-
35), seven tandem leucine rich repeats (LRR) (36-200) which are 24 amino acids in length, a C-
terminal flanking sequence (201-268), which forms a knot due to two disulfide linkages, and 
finally ends in a sulfated tyrosine rich anionic peptide (STRAP) region (269-282) (Figure 
10A).
95,96
 The structure of the N-terminal domain is almost “hook-like” and is involved in 
adhesion as well as signaling functions. The following interactions mediate the majority of the 
functions of the N-terminus of GPIbα (Figure 10B): 
1. Adhesion: Interaction with von Willebrand Factor (vWF), thrombospondin (TSP), P-selectin 
and integrin alpha M (ITGAM/αMβ2/MAC-1). 
2. Procoagulant functions: Interaction with α-thrombin, kininogen, factor XI and XII. 
3. Signalling: via GPVI, ITGAM/MAC-1 and FcγRIIa,  
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Figure 10. The GPIb-IX-V complex. (A) Cartoon representation of the GPIb-IX-V complex, 
showing the leucine-rich repeats, disulfide looped N- and C-terminal flanks, sulfated tyrosine 
containing sequences, and phosphorylation sites of the cytoplasmic tails.(B) Shows the 
functional binding sites of various ligands on the GPIb-IX-V complex. CaM : Calmodulin; FXI : 
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factor XI; FXII : factor XII; TSP: Thrombospondin-1; VWF : von Willebrand factor. Image 
taken from reference 96.
96
  
The length of the sialomucin core of GPIbα appears to be an important factor in 
regulating the availability of the N-terminus sequence for ligand binding, thus making it devoid 
of steric hindrance from platelet surface molecules.
97
 Hence the sequence is crucial for adhesion 
functions of platelets. The sialomucin chain is also recognized by cell wall proteins of bacteria 
such as Streptococcus gordonii to provide bacteria-platelet interaction.
98
 However, other bacteria 
require the N-terminal region of the protein, or bridging mechanism between GPIbα and vWF for 
bacteria-platelet interactions.
99-102
 The sialomucin core is also important for binding fVIIa, which 
might play a role in tissue factor-independent thrombin generation on activated platelet 
surface.
103
 
The intracellular cytoplasmic tail contains a filamin and signaling protein 14-3-3ζ binding 
region which are possibly involved in intracellular signaling.
104,105
 The 14-3-3ζ has been 
implicated in a toggle-switch mechanism which controls extracellular binding of vWF.
106
 
Filamin binding is believed to play roles in GPIbα-dependent adhesion, platelet shape and size, 
as well as raft localization of various receptors including the GPIb-IX-V complex.
96
 However, 
the exact consequences of the interaction remain more or less a mystery. 
Upon proteolytic digestion with Ca
2+
 activated protease calpain, the extracellular terminal 
region sheds off to give the soluble form of GPIbα, known as glycocalicin, which is present at 
normal levels of 1-3 μg/ml of blood.93,107,108 Apart from these functions, there is also evidence to 
show that GPIb-IX complex could be a regulator of systemic inflammation via interaction with 
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αMβ2 (MAC-1), and targeting this could prove promising as an anti-inflammatory and 
antithrombotic for sepsis and endotoxemia.
109-111
 
 
1.8 Interaction between Thrombin and GPIbα – Structure and Function 
The interaction between thrombin and GPIbα has been highly studied in the last 30 years. 
Initial mutagenesis studies had localized thrombin binding sites on GPIbα to the sulfated-
tyrosine rich anionic peptide (STRAP) region of the protein.
112
 On the other hand, until recently 
the binding site of GPIbα on thrombin was heavily debated. It has been demonstrated in several 
instances that such interaction causes allosteric changes in thrombin activity and specificity.
79,80
 
Earlier competitive studies with exosite 1 ligands such as hirudin, fibrinogen and 
thrombomodulin, showed that these ligands compete with GPIbα-thrombin interaction.80,113 
Furthermore, synthetic anionic peptide of GPIbα 269-287 was earlier found to interact with 
thrombin exosite 1 and enhance catalytic efficiency of thrombin towards small chromogenic 
substrates.
114
 However, such synthetic peptides were not revealed to have any sulfated tyrosines 
and there was no mention of sulfation step during their synthesis. In 2001, affinity studies on 
thrombin mutants revealed that GPIbα binds to exosite 2 mainly involving residues: R93A (22-
fold defect), R97A (8-fold defect), R101A (13-fold defect), R233A (29-fold defect), K236A (21-
fold defect), K240A (5-fold defect), and for the triple mutant R233A/K236A/Q239A (31-fold 
defect), while the Q239A and R67A forms did not show any significant affinity change.
115
 
Additional mutational studies and competition studies with low molecular weight heparin further 
demonstrated involvement of exosite 2 and also that binding of GPIbα to thrombin exosite 2 
induced an allosteric change in the activity of thrombin.
79
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To further complicate the scenario, two separate groups released crystal structures in July 
2003 having multiple thrombin molecules bound to GPIbα (Figure 11).116,117 In these crystal 
structures both exosite 1 and 2 binding to GPIbα was demonstrated and multiple thrombin 
molecules were found to bind to GPIbα. However, exosite 2-GPIbα interface was more similar as 
compared to residues involved in the exosite 1-GPIbα interface (Figure 11 and 12), suggesting 
that exosite 2 interaction was possibly tighter.
118
 It was suggested that thrombin could possibly 
also act as an adhesion molecule between platelets due to the fact that multiple thrombin 
molecules could bind in different poses. Further modeling suggested that GPIbα-thrombin 
interaction could be pH dependent and that binding to the STRAPs of GPIbα is likely to precede 
the binding of the rest of the molecule to the LRR of GPIbα in a loose manner.119 However, two 
recent publications showed that GPIbα binds to thrombin in 1:1 ratio in solution and that NMR 
studies have demonstrated that only exosite 2 is involved.
52,120
 Furthermore, it was confirmed in 
all above studies that the STRAP of GPIbα was essential for binding to thrombin.  
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Figure 11. Comparison of two reported crystal structures of GPIbα and thrombin. (A) Shows the 
individual crystal structures reported in PDB: 1OOK
116
 and 1P8V.
117
 (B) Shows the 
superimposed crystal structures showing that thrombin exosite-2 interacts in reproducible 
manner with the anionic peptide region of GPIbα. Image adapted from reference 118.118 
 
B
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Figure 12. GPIbα interaction with thrombin exosite 2. (A) Interaction of STRAP found in GPIbα 
with exosite 2 of thrombin. (B) A closer look shows how STRAP interacts with R126, K235, 
K236, R233, R101, R93 and K240 of thrombin exosite 2. 
GPIbα
Exosite 2
N-terminusA
B
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The physiological consequences of binding of thrombin to GPIbα are diverse. On one 
hand, binding of thrombin to GPIbα can result in activation of platelets; a pro-thrombotic 
effect,
121
 while on the other hand, GPIbα binding to thrombin causes allosteric inhibition of 
thrombin’s catalytic efficiency for fibrinogen cleavage, an anticoagulant effect.79,80 Additionally, 
isolated STRAPs from GPIbα (268-282) have been shown to bind to exosite 2 and allosterically 
inhibit thrombin-mediated activation of factor VIII.
82
 Reviewing the two peptide studies above, it 
is possible that sulfated tyrosines could direct GPIbα towards exosite 2 binding, while the non-
sulfated forms could bind via exosite 1. Even hydrogen-deuterium exchange (HDX) studies 
show that exosite 2 binding of GPIbα reduces HDX for sites distant from the binding interface 
suggesting long range conformational changes.
120
  
Platelet activation by thrombin involves proteolytic and non-proteolytic mechanisms, and 
intact GPIbα facilitates the platelet response to low but not high doses of thrombin.96 GPIbα acts 
as a cofactor for thrombin-dependent activation of PAR-1 as well as GPV.
81,122
 However, even 
active site blocked thrombin can activate platelets using GPIbα when PAR-1 or GPIIb/IIIa is 
inhibited, suggesting alternate routes of thrombin-GPIbα activation of platelets.123 Such 
mechanisms can possibly explain why active site thrombin inhibitors and anti-platelet regimens 
do not completely abrogate thrombosis/restenosis in patients. Targeting the interface of the 
interaction could provide a more useful antithrombotic. 
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1.9 Structure and Function of Factor XIa – An Emerging Target for Prophylactic 
Anticoagulation 
An ideal target for prophylactic anticoagulant therapy would be able to segregate 
hemostasis and thrombosis functions. Factor XIa (fXIa) is one such target that is believed to 
predominantly affect thrombus formation, rather than hemostasis. Although, the crystal structure 
of the entire apo-enzyme fXIa has not been resolved, there exists a crystal structure of the 
zymogen form of the enzyme fXI.
124
 Additionally, there exist several crystal structures of the 
catalytic domains, which can help shed light on the structure of the apo-enzyme in its active 
conformation. 
Structurally, factor XI is a unique 160kDa serine protease, which differs from vitamin-K 
dependent proteases in being a dimer of identical subunits (Figure 13A).
125
 Each subunit consists 
of 4 apple domains (A1, A2, A3 and A4) composed of 90-91 amino acids at the N-terminus, and 
a trypsin-like catalytic domain (CD) at the C-terminus, which sits on top of the apple domains in 
a cup and saucer arrangement. The two subunits of fXI are held together by an interchain 
disulfide bond, Cys
321
-Cys
321
.
124,126,127
 In the intrinsic pathway, factor XIIa (fXIIa) activates the 
zymogen factor XI (fXI) by catalyzing the cleavage of the peptide bond, Arg
369
-Ile
370
 on each 
subunit. Following activation, the enzyme is believed to undergo a dramatic shape change 
leading to a reorientation of the structure such that the catalytic domains of the two subunits 
come closer together (Figure 13B).
128
 Factor XIa has been shown to bind several biological 
macromolecules including high molecular weight kininogen,
129
 thrombin,
130
 heparin,
131-134
 factor 
IX,
135-137
 platelet glycoprotein Ib,
138,139
 apolipoprotein E receptor 2
140
 via allosteric sites (Figure 
13C). Allosteric modulators similar to its protease counterpart thrombin could yield controlled 
anticoagulant therapy.  
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Figure 13. Structure of factor XI and XIa. (A) The topology of the factor XI dimer with catalytic 
domain colored in red, and the four apple domains (gray, blue, orange and yellow) arranged in 
a cup and saucer arrangement with the Cys321 disulfide bond linking the two sub-units.
124
 (B) A 
C
B
A
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factor XIa model created on the basis of small-angle x-ray scattering and electron microscopy 
data in which the two catalytic domains (cat and cat’ in cyan and gray) come close to each 
other.
128
 (C) The factor XI dimer from two perspectives rotated 90° highlighting the binding 
locations of different modulators of factor XI.
126
 Sites for ligand binding are thrombin in red (T), 
high molecular weight kininogen in green (HK), GPIbα in black, heparin binding sites in blue 
(H1 and H2), factor IX in orange (FIX). In purple is shown the activation loop (AL) cleavage site 
(Arg360-Ile370) and the active site (AS) catalytic triad (Ser557, Asp462, and His413). Note: All 
images for this figure are taken directly from literature or corresponding supplementary 
information.   
 
Functionally, factor XIa activates factor IX (fIX), which in turn activates the downstream 
coagulation cascade. Thus, it ultimately contributes to the formation of a stable clot.
141
 Apart 
from fXIIa, fXI can undergo autoactivation. More interestingly, it can be activated by thrombin 
generated in small amounts in the early stages of coagulation in a process that is independent of 
fXIIa.
127,142
 In such a way, fXIa is responsible for rapidly regenerating thrombin which is 
essential for maintaining fibrin clot integrity, thus providing a positive feedback for 
coagulation.
143
 fXIa also enhances activation of thrombin-activable fibrinolysis inhibitor (TAFI), 
which is known to make clots less sensitive to fibrinolysis.
144
 Thus, targeting this upstream 
protease would leave the extrinsic and common pathways of the coagulation cascade intact, 
thereby preventing excessive bleeding.
145
  
Several studies have confirmed fXIa is a useful target for development of prophylactic 
anticoagulant therapy:
146
 for example, fXI-null mice, in comparison to wild type (WT) mice 
were clearly less susceptible to arterial and venous thrombosis when thrombosis was induced by 
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FeCl3,
147
 or laser injury models.
148
 This demonstrates that blocking fXIa could yield potential 
antithrombotic treatment. Additionally, fXI-deficient mice are healthy, thereby demonstrating 
that inhibition of the protease would result in safe anticoagulation.
149
 Another study involving 
neutralizing antibodies against fXI have also demonstrated a reduction in thrombus formation in 
rabbits.
150
 Even in humans, the natural deficiency of fXI (hemophilia C) (prominent in 
Ashkenazi Jews in Israel) results in a very benign bleeding phenotype compared to other 
hemophilia.
151-154
 This provides strong support that fXIa inhibition could provide safe 
anticoagulant modality. Recent reports have also linked fXI with inflammation. Thus inhibition 
of fXIa could prove useful in its treatment as well.
155-157
 
 
1.10 Current Thrombin, GPIbα and Factor XIa Inhibitors 
The well accepted concept that inhibition of thrombin would result in efficacious 
anticoagulation to prevent several cardiovascular diseases has been around for more than 3 
decades.
158
 On the other hand, the concept of inhibition of GPIbα to provide efficacious 
antithrombotic drugs is only surfacing recently.
159
 This has been largely due to the fact that 
GPIbα is a transmembrane protein, and technological limitations have limited the study of this 
target protein until recently. 
Ever since heparin’s discovery in 1916 by Jay Mclean, it has been a widely used 
antithrombotic drug.
160
 Polymeric heparin which is a glycosaminoglycan, is the most anionic 
macromolecule found within the body and is highly decorated with carboxylic acid and sulfate 
groups (Figure 14).
161
 It performs a number of interactions and is known to accelerate serpin- 
mediated inhibition of thrombin by: antithrombin, heparin cofactor II, protein C inhibitor and 
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protease nexin-1.
162
 Yet full length heparin suffers from several drawbacks such as difficulty in 
dosing, bleeding complications and severe side effects such as heparin-induced 
thrombocytopenia (HIT).
163
 Smaller versions of heparin such as low molecular weight heparin 
(LMWH) and heparin pentasaccharide (fondaparinux) seem to be safer. However, such smaller 
versions cannot participate in the bridging mechanism required to inhibit thrombin and therefore 
are only capable of inhibiting factor Xa.
72
 As a consequence, subcutaneous LMWHs and 
fondaparinux take time to achieve anticoagulation and the therapeutic range is difficult to predict 
in order to treat arterial thrombosis.
164
 
Another traditional anticoagulant, which has been used for more than 50 years is warfarin 
(Figure 14).
165
 Mechanistically, warfarin acts as an inhibitor of vitamin K epoxide reductase 
enzyme, by antagonizing vitamin K. This enzyme is crucial for the generation of the γ-
carboxyglutamic acid residues (GLA) which is an important post-translational modification in 
several proteases of the coagulation cascade including thrombin. The GLA domains of 
coagulation proteases help anchor them on cell surface membranes.
166
 The advantage of warfarin 
as a therapy is its ease of synthesis and oral bioavailability. However, warfarin therapy suffers 
from several food-drug as well as drug-drug interactions and can cause severe bleeding side 
effects. Consequently, warfarin therapy requires constant monitoring due to unpredictable 
pharmacokinetics and inter-patient variability.
167
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Figure 14. Structures of anticoagulants that have been introduced to the clinic including, 
heparin, warfarin, factor Xa inhibitors apixaban and rivaroxaban, thrombin inhibitors: 
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argatroban, melagatran, ximelagatran, dabigatran and dabigatran etexilate, and the hirudin 
derivatives: hirudin, lepirudin, desirudin, and bivalirudin. The image of the hirudin derivatives is 
taken directly from reference 168. 
168
 
 
Around two decades ago, a new class of peptide-based thrombin inhibitors was 
discovered from medicinal leeches, Hirudo medicinalis.
169
 This peptide was called hirudin 
(Figure 14), and was found clinically useful in patients who suffer from heparin-induced 
thrombocytopenia. Hirudin inhibits thrombin by a dual binding site mechanism, where an 
anionic C-terminal binds to exosite 1 while the N-terminal interacts with the active site to abolish 
catalytic activity. This dual binding capability makes hirudin a highly specific inhibitor of 
thrombin (Ki = 20 fM). Several derivatives of hirudin such as lepirudin, desirudin, bivalirudin 
were also developed and clinically used (Figure 14). Yet, being a peptide-based drug, these 
therapies suffered from quick proteolysis within the body and variation in clearance in patients 
with kidney disorders. These issues lead to dosing complications. Additionally, such molecules 
are difficult to produce on a large scale and are costly. Hence they can only be usefully as an 
alternative to UFH in patients with HIT.
170
  
Several novel small molecule anticoagulants based on the active site inhibitors of 
thrombin and factor Xa have emerged in the market in the past decade (Figure 14). These include 
thrombin inhibitors such as argatroban, melagatran (and its prodrug ximelagatran), dabigatran 
(and its prodrug dabigatran etexilate); and factor Xa inhibitors like apixaban and 
rivaroxaban.
171,172
 Out of these ximelagatran was taken off the shelf due to potential 
hepatotoxicity.
173
 While these drugs have an improved safety profile of anticoagulant therapy, 
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they are still not completely devoid of bleeding complications.
174
 This is understandable as these 
drugs target the active site of important coagulation proteases which results in complete knock-
out of these enzyme activities. Alternatively allosteric inhibitors are gaining importance in order 
to modulate coagulation protease activity in a more fine-tuned manner, with possibly better 
safety profiles.
3
  
In contrast to thrombin, no drug has reached the clinic which specifically targets platelet 
GPIbα-protein interactions. However, targeting the platelet GPIb complex is thought to be a 
potential route for development of antithrombotic drug development.
175
 Several antibodies, snake 
venom proteins, mutant thrombin molecules and peptides have been researched to bind to GPIbα 
and inhibit its various physiological functions.
175
 Such research has shown promise in in-vitro, 
ex-vivo and in-vivo animal models, that targeting GPIbα can yield efficient antithrombotic 
without causing undue bleeding problems.  However, only recently has there been any 
development of small molecules targeting specific protein-protein interactions involving GPIbα, 
such as the GPIbα-VWF interaction.176 To date, heparin is the only clinically used drug which 
has been shown to prevent thrombin-mediated platelet aggregation and activation, by targeting 
exosite 2 of thrombin and preventing GPIbα-thrombin interaction.177 
Similarly, factor XIa also has no established clinically used drug. Yet there is significant 
data to support the hypothesis that targeting factor XIa would provide a useful prophylactic 
anticoagulant that would possibly have fewer anticoagulant side effects.
145
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Chapter 2: Rationale 
2.1. Background 
The presence of thrombosis in several cardiovascular disorders stimulates an 
anticoagulant market which has grown to at least $10 billion.
3
 The anticoagulant market is 
dominated by the century old heparin and its derivatives. In the past decade, there has been an 
advent of novel active-site inhibitors of factor Xa and thrombin. Yet, there is not significant 
improvement of safety profiles of such drugs and long term side effects still remain questionable. 
The active site of serine proteases is highly conserved among various enzymes within the 
body.
34
 Due to this fact, targeting the active site specifically of a particular enzyme proves 
challenging and non-specific interactions could lead to long term toxicities. Such toxicity could 
possibly go unnoticed in short-term clinical trials. In comparison, allosteric sites on enzymes are 
relatively less conserved and offer a unique topographical identity, unlike active sites.
97
 
Furthermore, allosteric inhibition could possibly result in suppression of activity without 
complete blockage, resulting in safer anticoagulants with fewer bleeding complications. We have 
designed synthetic sulfated β-O4 lignin (SbO4L) as allosteric inhibitors of thrombin based on 
two elements (Figure 15): 
1. Structural resemblance to chemoenzymatically synthesized lignins 
2. Mechanistic resemblance to STRAP found in GPIbα 
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Figure 15. Rationale behind the creation of synthetic sulfated β-O4 lignin (SbO4L) polymer as a 
structural mimic of chemoenzymatically synthesized sulfated lignins (CDSO3, FDSO3, SDSO3) 
and mechanistic mimic of the STRAP of GPIbα.  
 
2.2. Structural Resemblance to Direct Exosite 2 Binding Inhibitors 
As seen earlier thrombin exosite 2 has been linked to modulation of active site function. 
Yet not all exosite 2 ligands induce a functional change in the catalytic activity of the enzyme. 
For example, heparin, which is the primary physiologic molecule that binds exosite 2 of 
thrombin, does not affect the catalytic efficiency alone, but acts as a cofactor for antithrombin 
III.
72
 On the other hand, a number of physiologic ligands show modification of thrombin activity 
or specificity. Due to the presence of such an allosteric network, it is not impossible to fathom 
the probability of allosteric inhibitors of thrombin which target exosite 2 directly. In general, it is 
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observed that sulfated aromatic scaffolds like sulfated tyrosines are capable of inhibiting 
thrombin via exosite 2-mediated allosterism. 
Overall, two pathways of research have emerged over the years to target thrombin 
exosite-2. One pathway involves the synthesis of DNA and RNA aptamers which inhibit 
thrombin by binding to exosite 2 of thrombin. Aptamers are small sequences of nucleic acids that 
are capable of binding a target protein or nucleic acid with high affinity.
178
 Using SELEX 
(Systematic Evolution of Ligands by Exponential Enrichment), the first aptamer based thrombin 
inhibitors were obtained by Bock et al., which was a 15-mer (TBA-15).
179
 This aptamer was 
found to bind at exosite 1 of thrombin.
68
 However later,  a 29-mer was identified (DNA 60-18) 
which binds at the heparin binding exosite 2 with 20 to 50-fold higher affinity compared to TBA-
15.
77
 The phosphate groups of the aptamers are capable of binding the electropositive residues on 
exosite 2 to enhance affinity, while the aromatic nature of the purines and pyrimidines can mimic 
the aromaticity of sulfated tyrosines to induce allosterism. Aptamer technology had gained a lot 
of popularity over a decade ago and had even reached Phase I clinical trials.
3
 However, due to 
instability of the aptamers, the molecules have a short in vivo half-life (~2 min), requiring high 
doses of aptamers.
180
 It is observed, that conformational stability of the aptamers is highly 
dependent on the cation it chelates.
181
 Current research is on-going to improve aptamer stability. 
However, the aptamer technology remains elusive for therapeutic value and has greater potential 
in developing diagnostic biotechnologies in the form of nanosensors to detect levels of thrombin 
and other biomedical applications.
181
  
The second approach was taken by our laboratory to mimic the sulfation patterns of 
heparin, while utilizing relatively hydrophobic aromatic lignins in order to induce inhibition of 
thrombin. The first generation lignins were synthesized utilizing chemoenzymatic methods in 
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order to form dehydropolymers (DHPs) of caffeic acid (CD), sinapic acid (SD) and ferulic acids 
(FD) using horse radish peroxidase enzyme.
182
 Lignin synthesis via chemoenzymatic synthesis 
leads to heterogeneity in the intermonomeric linkages. Such synthesis yields predominantly β-O4 
type linkage, followed by β5 type linkage. These DHPs were then sulfated to give the respective 
sulfated lignins CDSO3, SDSO3 and FDSO3. All sulfated lignins were found to be potent 
inhibitors of thrombin in nanomolar concentrations utilizing a direct allosteric mechanism which 
involves exosite 2.
183
 Such lignins were also potent in ex vivo blood and plasma assays.
184
 
However, lack of homogeneity in intermonomeric linkage results in a mixture of diverse 
scaffolds, which was not specific for only thrombin inhibition, as it was found that these sulfated 
lignins were capable of inhibiting other heparin binding serine proteases found in the body such 
as plasmin, factor XIa, factor Xa, cathepsin G and human leukocyte elastase with relatively good 
potency in nM-range (Table 1).
185,186
 The pursuit of identifying possible small molecule 
inhibitors from these parent lignins involved the exploration of selective synthesis of the β5 type 
linkage in the synthesis of benzofuran monomers, dimers and trimers.
187-189
 These studies 
revealed that exosite 2 of thrombin can be targeted using small molecules with low sulfation 
levels, and that there were different sub-pockets in exosite 2 which can possibly inhibit thrombin 
allosterically.  
What was largely unexplored was the β-O4 type intermonomeric linkage, which is in 
fact, the most predominant linkage found in chemoenzymatically synthesized lignins. Hence the 
rationale exists that the development of a chemically synthesized, homogenous SbO4L lignin 
polymer would likely contain a more potent, and possibly a more selective derivative of the 
DHPs, which could inhibit thrombin via an exosite 2-driven allosterism. 
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Table 1. Cross reactivity of chemoenzymatically synthesized lignins CDSO3, FDSO3 and 
SDSO3 against heparin binding serine proteases shows potent IC50. 
185,186
 
Proteases CDSO3*  FDSO3* SDSO3* 
Cathepsin G 232 ± 10  91 ± 7 105 ± 7 
Factor XIa 22 ± 2  105 ± 11 176 ± 11 
HLE  11 ± 2  9 ± 2 17 ± 1 
Factor Xa  34 ± 5  74 ± 8 121 ± 26 
Plasmin  240 ± 30  760 ± 20 1290 ± 60 
Thrombin  18 ± 2  29 ± 2 94 ± 4 
*(all concentrations are in nM) 
 
2.3. Mechanistic Resemblance Inspired from STRAP found in GPIbα 
As reviewed earlier (Chapter 1: Introduction), sulfated tyrosine rich anionic peptide 
(STRAP) region found in GPIbα is known to be crucial for the interaction between exosite 2 of 
thrombin and GPIbα. The physiological consequences of this interaction are both pro-thrombotic 
as well as anticoagulant. Thus, it would seem that nature has engineered a self check mechanism 
in order to control hemostatic and hemorrhaging factors utilizing this STRAP. By mimicking the 
STRAP using an aromatic sulfated scaffold like that found in SbO4L, we could possibly induce 
allosteric anticoagulant activity via inhibition of thrombin catalytic activity, while additionally 
obtaining a competitive antiplatelet activity by blocking the interaction of thrombin with platelet 
GPIbα. To date, no synthetic molecule has achieved this dual mechanism. 
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2.4. Questions to be answered 
There are several questions which needed to be answered in a sequential and systematic 
manner. These are as follows: 
1. Can we create a chemically synthesizable sulfated lignin with only β-O4 type 
intermonomeric linkage (SbO4L)? 
2. Can such molecules induce allosteric inhibition of thrombin by binding to exosite 
2? 
3. Can such a molecule compete with GPIbα? 
4. Will such a molecule be selective for thrombin compared to the parent sulfated 
lignins? 
5. Will such a molecule resemble the STRAP of GPIbα in its binding and allosterism 
mechanism? 
6. Will the inhibition of thrombin translate to potent anticoagulation? 
7. Will the competition with GPIbα translate to potent anti-platelet effects? 
8. Is the overall antithrombotic effect translatable to ex-vivo whole blood assays and 
in vivo in mice thrombosis assays? 
These studies will not only help identify a new class of antithrombotics but also shed 
light on possible interplay between the coagulation and platelet aggregation/activation pathways 
of hemostasis. Additionally, such molecules will highlight the applicability of STRAP-mimetics 
to target important protein-protein interactions which could result in molecules with varying 
functions.  
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Since, the β-O4 type intermonomeric linkage showed greater selectivity for thrombin in 
our studies, we rationalized that small molecules of the β-5 type linkage such as the benzofuran 
dimers and trimers, could possibly be more potent inhibitors for other coagulation cascade 
proteins. In particular, factor XIa is gaining wide importance as a potential target for developing 
prophylactic anticoagulants that could prevent cardiovascular diseases (as discussed in the 
Chapter 1: Introduction). We therefore sought to screen and characterize the inhibition of a 
library of sulfated small molecules and in particular the sulfated benzofurans for factor XIa 
inhibition activity. We have attempted to address questions regarding its mechanism and 
plausible binding site via competition assays, recombinant proteins and molecular modeling. 
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Chapter 3: Synthesis and Biochemical Analysis of Sulfated β-O4 Lignin (SbO4L) Polymer 
3.1 Introduction 
Recently, our laboratory designed the first few examples of exclusively allosteric 
coagulation enzyme inhibitors. These include the sulfated LMW lignins and sulfated 
benzofurans.
182-185,187,188,190
 Sulfated LMW lignins were originally designed to mimic the 
allosteric interaction of heparin with antithrombin, a key regulator of coagulation.
182,191
 Yet, 
detailed studies pointed to direct inhibition of thrombin as the major mechanism of 
action.
183,186,190
 Interestingly, these molecules were found to bind in the heparin-binding site of 
the enzyme and induce allosteric inhibition.
183
 However, being chemo-enzymatically 
synthesized, these sulfated LMW lignins were polydisperse with respect to their inter monomer 
linkages, with various possibilities such as β-O4, β-5, β-β, 5-5 and others.191 As a result of this 
hetereogeneity, they lacked selectivity and were capable of inhibiting serine proteases other than 
thrombin including factor Xa, factor XIa, human leucocyte elastase (HLE), plasmin, and 
cathepsin G (Table 1).
186
 Hence, further anticoagulation studies were not pursued for these 
molecules. 
We rationalized that a chemically synthesized molecule with greater homogeneity in the 
inter-monomeric linkage could possibly provide a more selective inhibitor. Further, such a 
molecule could possibly target exosite 2 in a manner similar to GPIbα. In this work, we report on 
the development of a sulfated β-O4 lignin (SbO4L), a chemically synthesized lignin, which 
exhibits highly selective and potent inhibition of human thrombin and plasmin in comparison to 
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other serine proteases due to its homogeneity in its inter-monomeric linkages compared to parent 
lignins. Furthermore, SbO4L shows lower potency for thrombomodulin bound thrombin, 
indicating that it could be useful in directing thrombin to more anticoagulant state. SbO4L also 
inhibits thrombin in a mechanism which is independent of antithrombin III. It inhibits thrombin 
through an allosteric process by binding in exosite 2. Mutagenesis data suggests that SbO4L 
binds at a site similar to the GPIbα-STRAP on the exosite 2 of thrombin. Additionally, SbO4L 
inhibition of thrombin is quantitatively and rapidly reversed by protamine. The work here 
demonstrates that small sulfated aromatic molecules could possibly be used to target the GPIbα-
STRAP binding site on the exosite 2 of thrombin for a novel mechanism of modulation of 
coagulation protease thrombin. 
 
3.2 Experimental 
Materials 
Human plasma proteases, thrombin and factors Xa, IXa, XIa and VIIa, recombinant tissue factor 
(rTF), activated protein C, human protein C and human plasma antithrombin were from 
Haematologic Technologies (Essex Junction, VT). Cathepsin G, chymotrypsin, kallikrein, 
trypsin, pancreatic porcine elastase (PPE), protamine sulfate, recombinant human 
thrombomodulin, bovine serum albumin and argatroban monohydrate were obtained from Sigma 
Aldrich (St. Louis, MO). Recombinant glycoprotein Ibα (GPIbα) was obtained from R&D 
Systems (Minneapolis, MN). Human leucocyte elastase (HLE) was from Elastin Products 
Company (Owensville, MO). Chromogenic substrates Spectrozyme TH, Spectrozyme FXa, 
Spectrozyme FIXa, Spectrozyme VIIa, Spectrozyme PCa, Spectrozyme PL, and Spectrozyme 
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CTY were obtained from Sekisui Diagnostics (Stamford, CT). Substrates N-succinyl-Ala-Ala-
Pro-Phe-pNA, N-(methoxysuccinyl)-Ala-Ala-Pro-Val-pNA, and N-succinyl-Ala-Ala-Ala-pNA 
were obtained from Sigma Aldrich (St. Louis, MO) and S-2266, S-2222 and S-2366 were 
obtained from Diapharma (West Chester, OH). Stock solutions of proteins were prepared in 20 
mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1 % polyethylene 
glycol (PEG) 8000 (thrombin and factor XIa) or 20 mM sodium phosphate buffer, pH 7.4, 
containing 0.1 mM EDTA and 0.1% PEG8000 (factor Xa). Factor VIIa stock solutions of 
proteins were prepared in 25 mM HEPES buffer, pH 7.4, containing 100 mM NaCl and 5 mM 
CaCl2, while factor IXa stock solutions were prepared in 100 mM HEPES buffer, pH 8.0 
containing 100 mM NaCl and 10 mM CaCl2. Porcine unfractionated heparin (MW 15000) was 
purchased from Sigma (St. Louis, MO). HirP, a Tyr63-sulfated hirudin-(54-65) peptide labeled 
with 5-(carboxy)fluorescein, i.e., [5F]-Hir[54-65](SO3-), was a gift from the Bock laboratory at 
Vanderbilt University. Recombinant thrombin mutants were a gift from Dr. Alireza Rezaie (Saint 
Louis University, MO). All other chemicals were analytical reagent grade from either Sigma 
Aldrich (St. Louis, MO) or Fisher (Pittsburgh, PA) and used without further purification. 
Synthesis of SbO4L 
For synthetic scheme see Figure 16, Pg. 69. 
4-(tert-butyldimethylsilyloxy)-3-methoxybenzaldehyde (2): In a 500ml round bottom flask add 
20 g (1 eq) of vanillin (1) in 120 ml of dichloromethane. To this mixture add 45.8 ml (3 eq) of 
diisopropyl ethyl amine (DIPEA). Add 23.8 g (1.2 eq) of tert-butyldimethylsilane chloride 
(TBDMSCl). Stir overnight under nitrogen. Add 100 mL water to quench the reaction and dilute 
with 300 ml dichloromethane. Separate out the organic layer. Wash the aqueous layer with 500 
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ml x 2 dichloromethane. Collect the organic layer and dry with sodium sulfate, filter and 
evaporate using rotary evaporator. Perform a normal silica column by first washing with hexanes 
followed by a gradient elution up to 10% ethyl acetate (EtOAc) in hexanes to obtain pure 
compound 2 (35 g, yield = 99%).  
1
H-NMR (CDCl3): 9.85 (CHO) (s, 1 H), 7.39-7.40 (C2-H) (d, 1 H), 7.35-7.37 (C6-H) (m, 1 H) , 
6.95-6.97 (C5-H) (d, 1 H), 3.87 (-OCH3) (s, 3 H), 1.01 (TBDMS-t-butyl) (s, 9H), 0.19 (TBDMS-
Me) (s, 6H).  
13
C-NMR (CDCl3): 190.95, 151.65, 151.35, 130.97, 126.17, 120.71, 110.18, 55.44, 25.59, 18.49, 
-4.56 
ethyl 3-(4-(tert-butyldimethylsilyloxy)-3-methoxyphenyl)-3-oxopropanoate (3): In a 500 ml 
round bottom flask, take 7.5 g of 2 and add a stir bar. To this add 250 ml dichloromethane. Flush 
nitrogen gas through the container and place on ice bath. Add 400 mg (0.05 eq) of niobium (V) 
chloride (NbCl5) as catalyst, which should be a fine, yellow colored powder. Seal the flask with a 
rubber stopper and parafilm or PTFE tape. Place a venting needle in the rubber stopper and 
slowly add 4.9 ml (1.4 eq) of ethyl diazoacetate solution (containing ≤ 15% dichloromethane) 
with care using a syringe. The reaction will effervesce vigorously for a few minutes with the 
release of nitrogen gas. Let the reaction mixture come to room temperature and stir for 3 hours. 
Monitor the reaction using TLC. Quench the reaction by adding 5 ml water and stir the flask 
open for 10 minutes. The solution will turn light yellow and a precipitate of NbCl5 will be 
obtained. Filter the solution through a short pad of celite to remove the catalyst, and wash the 
celite pad with 2 x 200 ml dichloromethane. Add 100 ml water and extract the organic phase. 
Wash the aqueous layer with 2 x 200 ml dichloromethane. Collect the organic layer and dry over 
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sodium sulfate, filter and evaporate using rotary evaporator making sure that the temperature 
does not exceed 35°C. Remove any unreacted ethyl diazoacetate by evaporation on high vacuum 
overnight. The pure product 3 can be isolated using normal silica column with gradient elution 
up to 10% EtOAc in hexanes to give a pale-yellow to colorless oil (8.5 g, yield = 86%). 
1
H-NMR (CDCl3): 7.53 (C2-H) (d, 1 H), 7.44-7.46 (C6-H) (m, 1 H) , 6.88-6.90 (C5-H) (d, 1 H), 
4.19-4.25 (-OCH2CH3) (q, 2 H), 3.95 (α-CH2) (s, 2 H), 3.87 (-OCH3) (s, 3 H), 1.25-1.28 (-
OCH2CH3) (t, 3 H), 1.01 (TBDMS-t-butyl) (s, 9H), 0.2 (TBDMS-Me) (s, 6H).  
13
C-NMR (CDCl3): 191.14, 167.73, 151.23, 150.70, 130.19, 123.16, 120.33, 111.41, 61.36, 
55.47, 45.79, 25.59-25.70, 18.49, 14.08, -4.57. 
ethyl 3-(4-hydroxy-3-methoxyphenyl)-3-oxopropanoate (4): Take 6.3 g of 3 in a 250 ml round 
bottom flask and add 10 ml dimethylformamide (DMF) to it. Add 3.1 g (3 eq.) of potassium 
fluoride (KF) and catalytic quantity of acetic acid (0.01 ml). Stir the reaction vessel for 12 hours. 
Add 50 ml mildly-acidified water to quench the reaction. Extract the aqueous layer with 250 x 3 
washes of ethyl acetate. Collect the organic extracts, dry over sodium sulfate and filter. 
Evaporate the filtrate using rotary evaporator. The product 4 is purified using normal silica 
column with step gradient elution up to 70% EtOAc in hexanes in 10% increments over two 
column volumes (3.98 g, yield = 94%). 
1
H-NMR (CDCl3): 7.55-7.56 (C2-H) (d, 1 H), 7.50-7.52 (C6-H) (m, 1 H) , 6.95-6.98 (C5-H) (d, 
1 H), 6.20 (-OH) (s, 1 H), 4.20-4.25 (-OCH2CH3) (q, 2 H), 3.96 (α-CH2) (s, 2 H), 3.95 (-OCH3) 
(s, 3 H), 1.25-1.29 (-OCH2CH3) (t, 3 H).  
13
C-NMR (CDCl3): 190.96, 167.74, 151.00, 146.80, 129.06, 124.17, 113.98, 110.11, 61.42, 
56.09, 45.69, 14.08. 
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ethyl 2-bromo-3-(4-hydroxy-3-methoxyphenyl)-3-oxo-propanoate (5): In a 250 ml round 
bottom flask, take 1.2 g of compound 4. Place the flask on an ice bath and add 40 ml of 
dichloromethane and then 1.17g (1.05 eq) bromodimethylsulfonium bromide (BDMS) as a 
yellow powder. Stir the reaction mixture till it reaches room temperature (30 mins). Add 50 ml 
water and another 50 ml of dichloromethane. Separate the organic layer. Wash the aqueous layer 
with 3 x 50 ml dichloromethane. The collected organic layer is dried over sodium sulfate, filtered 
and evaporated using rotary evaporator taking care that the temperature does not exceed 35°C. 
The pure monomer 5 is obtained without any further purification (1.55g, yield = 97%). 
1
H-NMR (CDCl3): 7.58-7.60 (C2-H, C6-H) (m, 2 H) , 6.97-6.99 (C5-H) (d, 1 H), 6.23 (-OH) (s, 
1 H), 5.65 (α-CHBr) (s, 1H), 4.27-4.33 (-OCH2CH3) (q, 2 H), 3.98 (-OCH3) (s, 3 H), 1.26-1.30 
(-OCH2CH3) (t, 3 H).  
13
C-NMR (CDCl3): 186.64, 165.37, 151.51, 146.90, 126.14, 124.70, 114.12, 111.05, 63.23, 
56.16, 46.20, 13.90. 
β-Keto-Ester Polymer (6): In a flask containing the monomer 5 (0.97 g) (or other appropriate 
monomer) in anhydrous DMF (5 mL), anhydrous K2CO3 (0.58 g) was added and stirred under 
nitrogen. After 24 h the reaction mixture was poured onto ice-water mixture (120 ml) and the pH 
adjusted to ~2.5 with 2M HCl. The precipitated polymer 6 was filtered, washed with water and 
lyophilized to remove moisture. (≈700 mg per reaction) 
NMR characterization showed the following corresponding broad peaks for 
1
H-NMR (DMSO-
d6): 7.46-7.78 (C2-H and C5-H), 6.91-7.14 (Cβ-H), 6.52-6.66 (C6-H), 4.19-4.20 (-OCH2CH3), 
3.79-3.81 (-OCH3), 1.12-1.22 (-OCH2CH3).  
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13
C-NMR (DMSO-d6) 188.53, 189.08 (Cα), 165.81,166.02 (Cγ), 153.16, 150.93, 149.48, 149.01, 
147.64, 128.33, 125.51, 124.75, 123.73, 115.17, 114.08, 113.91, 113.09, 112.51, 112.30 
(aromatic carbons), 78.54, 78.37 (Cβ), 61.80, 61.67 (-OCH2CH3), 55.78, 55.58 (-OCH3), 13.77 
(-OCH2CH3). 
Reduced Polymer (7): 600 mg of solid 6 was suspended in methanol (10 ml) followed by careful 
addition of NaBH4 (683 mg). The mixture was gradually heated to 50°C as it turned clear, and 
was stirred for 24 h. The solution was then neutralized with acetic acid and poured into 0.5M 
HCl (200 mL) to precipitate the reduced crude polymer 7, which was isolated by filtration 
through sintered glass funnel, washed with water and lyophilized overnight. Dissolution and 
preferential precipitation using 1,4-dioxane and diethyl ether helped remove low molecular 
weight chains of the polymer and precipitate the high molecular weight chains. The precipitated 
pure reduced polymer 7 was filtered and dried using vacuum. (≈150 mg per reaction) 
NMR characterization showed the following corresponding broad peaks for 
1
H-NMR (DMSO-
d6): 4.75 (Cα-H), 4.28 (Cβ-H), 3.20-3.71 (Cγ-H and –OCH3), 7.02 (C2-H), 6.94 (C5-H), 6.85 
(C6-H).  
13
C-NMR (DMSO-d6): 70.8, 71.4 (Cα), 83.6, 84.4 (Cβ), 59.8, 59.9 (Cγ), 55.4 (-OCH3), 134.7-
135.0 (C1), 111.3-111.7 (C2), 148.9 (C3), 146.7-147.0 (C4), 114.5-115.0 (C5), 119.4-119.7 
(C6). 
SbO4L: 50 mg of the reduced polymer 7, so obtained was made to react with triethylamine-
sulfur trioxide complex (600 mg) in anhydrous DMF (5 ml) at 65 °C for 24 h under reflux with 
nitrogen.  Following the reaction, 30% (w/v) aqueous sodium acetate (35 ml) was added and the 
mixture stirred overnight to exchange the counter-ions of the sulfate groups. The solution was 
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then poured into ice-cold ethanol (100 ml) to precipitate crude SbO4L, which was filtered and 
washed twice with ice-cold ethanol (10 ml each) to remove any unreacted polymer. The 
recovered solid was desalted using FloatALyzer G2 (Spectrum Labs) dialysis tubes (MWCO 0.1-
0.5 KDa) or using ultra-filtration membrane (Ultracel YM1, NMWL 1,000 Da) with a stirred cell 
under nitrogen at 30 psi (Millipore). Lyophilization of the retentate solution gave SbO4L. 
(≈100mg per reaction)  
NMR characterization showed the following corresponding broad peaks for 
1
H-NMR (DMSO-
d6): 6.77 (aromatic protons), 3.47-4.27 (Cα-H, Cβ-H, Cγ-H, -OCH3).  
Elemental Analysis of SbO4L was carried out by Atlantic Mircolabs (Norcross, GA). Anal. 
Calcd. for 22-mer SbO4L with 27 sulfate groups and associated with 24 waters is: C, 35.20; H, 
3.85; S, 11.53. Found: C, 35.39; H, 4.15; S 11.54. 
13
C-NMR could not give sufficient signal even at high concentrations of the sample, possibly due 
to the presence of a wide variety of sulfation patterns and molecules of different chain lengths. 
Extensive characterization of SbO4L was therefore carried out using size exclusion 
chromatography and reversed-phase ion-pairing chromatography as described below. 
 
Size Exclusion Chromatography of SbO4L 
Size exclusion chromatography (SEC) was used to assess the molecular weight of the 
synthesized SbO4L. For SEC analysis the Asahipak GS320 HQ column (Shodex, New York, 
NY) was used with an isocratic flow rate of 0.7 mL/min of 0.1 N NaOH at pH 11.0. The 
wavelengths of 280nm were used to detect the eluted polymer. Polystyrene sulfonate (PSS) 
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standards were used for calibration purposes. The relationship between log of the molecular 
weight and the elution volume (V) of the standards was linear with a R
2
 of 0.98. The 
chromatograms obtained were sliced into 1000 time periods providing the MR for each period 
and the corresponding intensity of absorbance (A) as the number of polymeric species with the 
particular MR. These values  were then utilized to calculate the number average molecular 
weights (MN) and the weight average molecular weight (MW) and the polydispersity (P) using the 
following equations: 
    
       
   
   (Eq. 1) 
   
       
 
       
  (Eq. 2) 
  
  
  
    (Eq. 3) 
The peak molecular weight (MP) was calculated from extrapolation in the equation obtained from 
the plot of log MW of PSS standards vs elution volume. 
 
Reversed-Phase Ion-Pairing (RPIP) UPLC-MS 
Three different batches of SbO4L synthesized were tested for similarity using a method of RPIP-
UPLC-MS which was adapted from previous report.
192
 Briefly, a Waters Acquity H-class UPLC 
system equipped with a PDA detector and a tandem quadrupole (TQD) mass spectrometer was 
used. A 1.7 μm BEH C18 column (2.1 mm X 150 mm) was used for fingerprinting, which 
required 5 μl injection of SbO4L (400 μg/mL) at 30 ± 2 °C and a solvent system composed of 
10% v/v acetonitrile-water (solvent A) and 75% v/v acetonitrile-water (solvent B). Both solvents 
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contained n-hexylamine (25 mM) as an ion-pairing agent along with acid modifier formic acid 
(0.1%). Resolution of SbO4L was achieved using a linear gradient from 0% to 100% solvent B 
in 40 mins. Absorbance was monitored from 230-400 nm and the eluent was directly injected 
into the mass spectrometer. ESI-MS detection conditions utilized positive ion mode with 
capillary voltage of 4kV, cone voltage of 20 V, desolvation temperature of 350 °C and nitrogen 
gas flow rate of 650 L/h. Mass scans were collected in the range of 500-2048 m/z within 0.6 s to 
obtain the UPLC-MS fingerprints. 
 
Direct Inhibition of Enzymes of the Coagulation Cascade 
Inhibition of various coagulation cascade enzymes like thrombin, factors Xa, IXa, XIa and VIIa 
by SbO4L was characterized using chromogenic substrate hydrolysis assays, as described 
previously in literature.
183,186
 Briefly, a 10 µl aqueous solution of SbO4L was diluted with 930 µl 
of an appropriate buffer in PEG20000-coated polystyrene cuvette. Plasmin, recombinant tissue 
factor – factor VIIa inhibition was studied in a 96-well microplate format, as described below in 
the section on heparin-binding serine proteases, except for measuring the activity over the full 
range of SbO4L concentrations. The buffers used in these experiments were as follows: 20 mM 
Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % PEG8000 for 
thrombin, factor Xa and factor XIa; 100 mM HEPES buffer, pH 8, containing 100 mM NaCl and 
10 mM CaCl2 for factor IXa; 25 mM HEPES buffer, pH 7.4, containing 100 mM NaCl and 5 
mM CaCl2 for factor VIIa and factor VIIa–tissue factor complex; and 50 mM Tris-HCl, 150 mM 
NaCl and 0.1% PEG8000, pH 7.4 for plasmin. This was followed by addition of a 10 µl solution 
of the protease (stock concentrations used: 600 nM thrombin, 108 nM factor Xa, 152 nM factor 
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XIa, 22.5 μM factor IXa, 4 μM factor VIIa). The enzyme and inhibitor were incubated at 37°C 
for 10 minutes. In case of fVIIa–tissue factor complex, 10μl of 1:1 mixture of 266 nM factor 
VIIa and 800 nM recombinant tissue factor was added as a complex. Following incubation, a 50 
µl (or 5 μl in case of plasmin and recombinant tissue factor-VIIa assay) solution of chromogenic 
substrate was rapidly added and the residual enzyme activity was measured from the initial rate 
of increase in A405. The chromogenic substrates used were Spectrozyme TH (H-D-
hexahydrotyrosol-Ala-Arg-p-nitroanilide), Spectrozyme FXa (methoxycarbonyl-D-
cyclohexylglycyl-Gyl-Arg-p-nitroanilide), Spectrozyme FIXa (D-Leu-Phe-Gly-Arg-p-
nitroanilide), Spectrozyme FVIIa (methanesulphonyl-D-cyclohexylalanyl-butyl-Arg-p-
nitroanilide), Spectrozyme PL (H-D-norleucyl-hexahydrotyrosol-lysine-para-nitroanilide). 
Inhibition of factor XIa was studied using Spectrozyme FXa. Relative residual proteinase 
activity at each concentration was calculated using the activity measured under otherwise 
identical conditions, except for the absence of SbO4L. The IC50 was calculated from the 
regressional analysis using logistic equation 4. 
     
     
                              
   (Eq. 4) 
  In this equation Y is the fractional residual protease activity, i.e., the ratio of protease 
activity in the presence of inhibitor to that in its absence; YM and Y0 are the maximum and 
minimum fractional residual activities, respectively; IC50 is the concentration of the inhibitor that 
results in 50% inhibition of enzyme activity; and HS is the Hill slope. 
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Inhibition of Other Heparin-Binding Serine Proteases 
Being highly sulfated, it is important to check if SbO4L can inhibit other proteases by mimicking 
heparin. The direct inhibition of other heparin binding serine proteases was tested against SbO4L 
using the chromogenic substrate hydrolysis assay (similar to above) using a 96-well microplate 
format with conditions adapted from previous literature.
186
 Briefly, 5 μl of SbO4L (1.62mg/ml) 
was diluted with 85 μL of an appropriate buffer at either room temperature or 37°C followed by 
addition of 5 μl of the protease solution and incubation for 5 min. The activity of the protease 
was assessed by addition of 5 μl of chromogenic substrate and measuring the initial rate of 
increase in the absorbance at 405nm (<10% substrate consumption). The optimal assay 
conditions for the heparin-binding serine proteases were as follows: 50 mM Tris-HCl, 50 mM 
NaCl, pH 8.0, at room temperature for cathepsin G and Human Leukocyte Elastase (HLE); 20 
mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2 and 0.1% PEG8000, pH 7.5, at 37°C for Porcine 
Pancreatic Elastase (PPE) and kallikrein; 50 mM Tris-HCl, 125 mM NaCl and 10 mM CaCl2, pH 
8.0, at 37°C for activated protein C (APC); and 50 mM Tris-HCl, 150 mM NaCl and 0.1% 
PEG8000, pH 7.4, at 37°C for trypsin and chymotrypsin. The enzyme concentrations used in 
these experiments were 200 nM cathepsin G, 1 μg/ml HLE, 0.005 U/ml kallikrein, 0.0125 U/ml 
PPE, 7 nM APC, 0.5 μg/ml chymotrypsin and 0.145 μg/ml trypsin. Chromogenic substrates used 
were 1 mM N-succinyl-Ala-Ala-Pro-Phe-pNA (cathepsin G); 100 μM N-(methoxysuccinyl)-Ala-
Ala-Pro-Val-pNA (HLE); 50 μM H-D-Val-Leu-Arg-pNA (S-2266) (kallikrein), 100 μM N-
succinyl-Ala-Ala-Ala-pNA (PPE); 200 μM H-d-(γ-carbobenzoxyl)-Lys-Pro-Arg-pNA 
(Spectrozyme PCa) (APC); 160 μM N-benzoyl-Ile-Glu-(-OR)-Gly-Arg-pNA (S-2222) (trypsin) 
and 250 μM H-D-Ala-Pro-Phe-pNA (Spectrozyme CTY) (chymotrypsin). The percent residual 
activity of the enzyme in the presence of the inhibitor with respect to control of no inhibitor was 
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calculated from the initial velocity of the enzyme measured as the increase in the absorbance at 
405nm as a function of time. Each assay was performed in duplicate. 
 
Effect of SbO4L on Antithrombin III Inhibition 
SbO4L inhibition of thrombin in the presence and absence of antithrombin III (ATIII) was 
performed using a 96-well microplate assay that was adapted from previous reports.
182
 Briefly, in 
180 µl of 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1% 
PEG8000 a 5 µl aqueous solution of SbO4L was added. This was followed by addition of 5 µl of 
thrombin to give a final concentration of 6 nM and 5 µl of antithrombin to give final 
concentration of 200 nM ATIII in each well. The mixture was incubated at 37°C for 10 min 
followed by addition of 5 μl of 5 mM Spectrozyme TH. The residual enzyme activity was 
determined from the initial rate of increase in absorbance at 405 nm. The apparent IC50 was 
calculated using logistic equation 4 along with other inhibition parameters such as YM, Y0 and 
HS. 
 
Inhibition of Activation of Protein C by Thrombin-Thrombomodulin Complex in the presence of  
SbO4L 
The protocol for measuring the activation of protein C by thrombin–thrombomodulin (TH-TM) 
complex was adapted to a 96-well format from the literature.
193
 Briefly, in 70 μl of 50 mM Tris-
HCl buffer, pH 7.4, containing 100 mM NaCl, and 1 mM CaCl2, 5 μl of SbO4L was added at 
concentrations ranging from 2.3 ng/ml to 2.3 mg/ml at 37°C, followed by addition of 5 μl of 
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thrombin (240 nM) and 5 μl of TM (400 nM). The mixture was incubated for 10 min and 5 μl of 
protein C (10 μM) added and incubated at 37°C for another 10 min. After this period, further 
generation of activated protein C (APC) was quenched by the addition of 5 μl mixture of  10 mM 
EDTA and 16 μM argatroban (≈20x Ki). The APC generated was quantified from the initial rate 
of chromogenic substrate hydrolysis of 400 μM S-2366. The percent activation of protein C was 
calculated from initial rate in the presence and absence of SbO4L and the apparent IC50 was 
calculated in a similar manner using equation 4. 
 
Variation of SbO4L Inhibition on Various Types of Thrombins 
In order to establish inter-species variability in the inhibitory potential of SbO4L and efficacy 
against thrombin degradation enzymes, chromogenic substrate hydrolysis assays were performed 
on human, mouse, bovine and gamma thrombin using a 96-well microplate format. Briefly, 5μL 
of either water or SbO4L at concentrations ranging from 2.3 ng/ml to 2.3 mg/ml was diluted with 
185μL of 20mM Tris-HCl buffer, pH 7.4, containing 100mM NaCl, 2.5mM CaCl2, and 0.1% 
PEG 8000 in a 96-well polystyrene microplate at 37°C. To this was added 5μL of thrombin to 
give 6nM of the different thrombin in separate series. The solution was incubated for 10 minutes, 
following which 5μL of 5mM chromogenic substrate Spectrozyme TH was added. The residual 
activity of thrombin was determined by monitoring the initial rate of product formation at 405 
nm wavelength. The percent residual activity and the IC50 was determined using logistic equation 
4. 
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Fibrinogen Assay 
To test if SbO4L was active against physiologically relevant substrate fibrinogen, the following 
microplate assay was performed. Briefly, in 35 μL of buffer (20mM TrisHCl, 100mM NaCl, 
2.5mM CaCl2 0.1% PEG8000, pH 7.4), 10 μL of thrombin (300nM) was added along with either 
5μL of water as control or SbO4L at concentrations ranging from 2.3μg/ml to 5.6 mg/ml. The 
mixture was incubated for 10 minutes at 37°C, after which 10 μL of this reaction was added to 
140 μL of 250 nM of fibrinogen. The formation of fibrin mesh was observed as absorbance at 
600 nm for the first 100 seconds after initiation of the reaction. The slope was used to get the rate 
of enzyme activity towards fibrinogen cleaving activity. The percent residual activity and IC50 
were calculated in a manner similar to that done for the peptide chromogenic substrate reactions 
using equation 4. 
 
Michaelis Menten Kinetics 
To assess the nature of the inhibition of thrombin by SbO4L Michaelis-Menten kinetics 
experiments were performed in the presence of various concentrations of the inhibitor using 
previously reported protocols.
183,188,189
 The initial rate of Spectrozyme TH hydrolysis by 3 nM 
thrombin was monitored from the linear increase in absorbance at 405 nm corresponding to less 
than 10% consumption of the substrate. The initial rate was measured as a function of substrate 
concentrations (0.6 to 20 µM) in the presence of a fixed concentration of SbO4L (0–2.3 μg/ml) 
in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2 and 0.1 % 
PEG8000 at 25°C in a cuvette. Standard Michaelis-Menten equation was used to calculate KM 
and VMAX (Eq. 5).  
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  (Eq. 5) 
 
Competition with Heparin, Hirugen Peptide and recombinant GPIba 
SbO4L-dependent thrombin inhibition studies in the presence of competitors were performed as 
described earlier.
183
 SbO4L (0–23 μg/ml) was incubated with either HirP (0 – 86 nM) or porcine 
UFH (0–100 μM) and thrombin (5 nM) in 20 mM Tris-HCl buffer, pH 7.4, containing 100 mM 
NaCl, 2.5 mM CaCl2 and 0.1 % PEG 8000 at 25°C in PEG20000-coated polystyrene cuvettes for 
10 minutes. For competition with GPIbα, SbO4L (0-1mg/ml) was incubated with GPIbα (0-
458nM) and thrombin (6 nM) in 10mM HEPES buffer with 10mM Tris-HCl, pH 7.8 containing 
100mM NaCl and 0.1% PEG 8000 in 96-well plate for 10 minutes. Following incubation, 
Spectrozyme TH (100 μM) was added and the initial rate of 405 nm absorbance change was 
measured. The dose-dependence of the fractional residual protease activity at each concentration 
of the competitor was fitted by equation 1 to calculate the IC50,app of inhibition. The molecular 
weight of porcine UFH was assumed to be 15,000, while its affinity was measured earlier in the 
laboratory (15.6±3.1 μM).183  
To quantify the degree of competition of SbO4L with its competitors, the Dixon-Webb 
relationship was used to calculate the apparent IC50,app of the inhibitor in the presence of a 
competitor with known affinity (Kcompetitor).
183,190
 The equation is given as: 
                       
            
           
   (Eq. 6) 
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Mutagenesis Studies 
To localize the important residues for binding of SbO4L in the exosite 2 of thrombin, SbO4L 
inhibition of various thrombin mutants was performed. The IC50 of SbO4L against recombinant 
mutants of thrombin was measured using the chromogenic hydrolysis assay in a 96-well format. 
In general, SbO4L (0-2 mg/ml) was incubated with individual mutants of thrombin (6 nM) in a 
20 mM Tris-HCl buffer containing 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000 at a pH 7.4 
for 10 minutes. Following this, substrate Spectrozyme TH (100 μM) was added to the reaction 
and the intial rate of increase in absorbance at 405nm was measured. The rate of initial 
hydrolysis was used to calculate residual thrombin activity, which was used to calculate the IC50 
from equation 4. 
 
Probing Allosteric Change in Active Site using Quenching 
Accessibility of the active site in the presence of SbO4L can be probed using a labeled enzyme 
and a collisional quencher.
194
 199 μL of buffer containing 20 mM Tris HCl, 100mM NaCl, 2.5 
mM CaCl2, 0.1% PEG 8000 at pH 7.4 was taken in a quartz cuvette. To this was added 1 μL of 
fFPR-Thrombin such that the final concentration of the enzyme was 170 nM. 3 μL of either 
water or 3mg/mL SbO4L was added. The fluorescence intensity was monitored using a QM4 
fluorometer (Photon Technology International, Birmingham, NJ) which was thermostated with a 
water bath at 25°C using excitation and emission wavelengths of 490 nm and 522 nm 
respectively, with slit-widths of 4nm each. The solutions were titrated with increasing 
concentrations of the quencher acrylamide (stock of 10 M with 1 μL additions) and the 
fluorescence intensity monitored after each addition. 
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The ratio of the fluorescence without the quencher (F0) to the fluorescence in the presence of 
various concentrations of the quencher (F) can be plotted against the quencher concentration (Q) 
to yield a linear relationship which can fit the Stern-Volmer relationship
194
: 
  
 
                      (Eq. 7) 
Where kq is the bimolecular quenching constant,    is the fluorophore lifetime in the absence of 
the quencher and Q is the concentration of the quencher. KSV in this case is the Stern-Volmer 
constant and is equal to kq  . 
 
Quantitating Number of Ionic Interactions Involved by Salt Dependence Studies on Affinity 
To study the salt dependence of SbO4L interaction with thrombin, a fluorescence binding study 
was carried out using buffers having different concentrations of sodium chloride. Briefly, in 199 
μL of buffer containing 20 mM Tris HCl, 2.5 mM CaCl2, 0.1% PEG 8000 at pH 7.4 containing 
various concentrations of NaCl (100-200 mM), 1μL of fFPR-Thrombin was added, to give a final 
concentration of 170 nM in the quartz cuvette. The experiments were performed using a QM4 
fluorometer (Photon Technology International, Birmingham, NJ) which was thermostated with a 
water bath at 25°C. The mixture was then titrated with SbO4L and the decrease in fluorescence 
was monitored using excitation and emission wavelengths of 490 nm and 522 nm respectively, 
with slit widths of 4nm each. The decrease in fluorescence signal was fit to a quadratic equation 
to obtain the dissociation constant at various concentrations of salt: 
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Where, ΔF represents the change in fluorescence of fFPR-Thrombin at each addition of SbO4L 
from the initial fluorescence F0. ΔFMAX represents the maximal change in fluorescence observed 
when the enzyme is saturated with the inhibitor. [E]0 is the enzyme concentration which is a 
constant for the experiment, while [SbO4L]0 is the concentration of the inhibitor during the 
titration. KD is the dissociation constant of the complex. 
The dissociation constant (KD) so obtained was further expressed as a linear function of the salt 
concentration according to the expression: 
-log KD = A0 + Γsalt log [salt]  (Eq. 9) 
The slope of the line yields Γsalt which represents a thermodynamic measure of the effect of salt 
concentration on binding equilibria, which can be compared with other exosite binding ligands.  
 
Reversal of SbO4L Mediated Thrombin Inhibition by Protamine 
To test whether SbO4L inhibition of thrombin can be reversed by protamine, a solution of 
SbO4L (575 ng/ml) along with thrombin (6nM) in a 20 mM Tris-HCl buffer, pH 7.4, containing 
100 mM NaCl, 2.5 mM CaCl2 and 0.1% PEG8000 at 37°C was gradually titrated with protamine 
(4.9 ng/ml to 14.8 mg/ml) such that the final volume was 195 μl. The solution was incubated for 
10 minutes followed by addition of 5 μl of Spectrozyme TH (5 mM) and the increase in 
absorbance at 405 nm observed. In the absence of protamine, SbO4L gave ~50% inhibition of 
thrombin at 37°C. Protamine alone did not affect the activity of thrombin as assessed by 
appropriate controls. The sigmoidal gain in thrombin activity could be fitted by the equation 4 to 
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obtain the effective concentration of protamine necessary to recover thrombin from SbO4L 
inhibition by 50%. 
 
 
3.3 Results 
Synthesis of SbO4L  
The synthesis of SbO4L was accomplished using a 7-step synthetic protocol starting from 
commercially available vanillin (1). The key to the formation of the β-O4 lignin 7 is in the 
formation of reactive monomer 5. The synthesis of monomer 5 was previously reported,
195
 
however, the strategy was not reproducible and often yielded lower yields than reported. This 
was largely due to the fact that the deprotection of the benzyl group involved palladium-
catalyzed hydrogenation which also resulted in the reduction of the α-keto to an alcohol. This 
resulted in lower overall yield. Additionally, the β-alcohol ester side product was rendered less 
reactive for bromination at the α-position, and therefore could not be used further. As a result we 
developed a novel strategy for synthesis using TBDMS protection (Figure 16).  
TBDMS protection of vanillin afforded compound 2 in almost quantitative yields at a 
large scale (>20 g). Synthesis of β-keto ester from aldehydes was reported earlier for vanillin 
derivatives with benzyl protecting group as a two step process using reactive reagents such as 
diethyl aluminium.
195
 Alternatively, the paper also proposed the synthesis of beta-ketoester in a 
single step from acetovanillone using sodium hydride and ethyl carbonate. Such reactions could 
not work with TBDMS protection. Hence we adapted a milder method utilizing niobium (V) 
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chloride and ethyldiazoacetate.
196
 The reaction had to be optimized for use with TBDMS 
protecting group with a reduction in temperature while addition of ethyldiazoacetate to prevent 
deprotection and other side reactions due to the heat generated from the reaction. This method 
produced the beta-ketoester 3 on a sufficiently large scale (>7 g) with good yield.  
Deprotection of the TBDMS group was then performed using potassium fluoride with 
catalytic quantities of acetic acid to produce 4 in good yields and scale (> 3 g). Bromination was 
previously reported to have been performed using elemental bromine.
195
 Use of elemental 
bromine requires special care as it is highly toxic. Furthermore, handling of the reagent and 
weighing can be difficult. As a result, one can often get higher orders of bromination or 
incomplete reactions. We therefore explored an alternative to synthesize the α-bromo. Selective 
mono-bromination at the α-position of the β-keto ester was performed with the use of 
bromodimethyl sulfonium bromide (BDMS) reagent.
197
 BDMS reagent can be freshly prepared 
to yield a yellow powder which can be easily handled. This reaction was surprisingly very clean 
and the product 5 formed required no purification apart from simple aqueous work up. Since α-
bromo-β-keto esters are reactive and susceptible to degradation, fresh monomer 5 was produced 
every time prior to polymerization.  
Polymerization of 5 using K2CO3 to form 6 and its subsequent reduction using NaBH4 to 
form the β-O4 lignin 7 was performed using methods previously described.198,199 While the 
polymerization step gave good yields, reduction and subsequent purification to form 7 showed 
some loss of compound due to separation of lower molecular weight species from the polymer 
by precipitation. The NMR of the products obtained for these two steps matched well with the 
literature records.
198,199
 A final step of sulfation was adapted from the sulfation methodologies 
used to create the chemoenzymatically synthesized lignins.
182,183
 The β-O4 lignin polymer was 
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reacted with sulfating agent following which the counterion on the sulfated polymer was 
exchanged using sodium acetate resulting in a highly water soluble polymer which could be 
purified by precipitation (with ethanol) and dialysis/ultrafiltration to afford purified SbO4L. 
NMR characterization of SbO4L was challenging due to the fact that it was a heterogeneous 
mixture. Further characterization of SbO4L was carried out using size exclusion chromatography 
and reversed-phase ion-pairing chromatography, to establish reproducibility in the synthesis, as 
well as to determine length of the polymeric species.  
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Figure 16. Synthetic scheme for production of SbO4L 
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SbO4L is a Sulfated Polymeric Species which can be Reproducibly Synthesized 
Characterizing sulfated polymers is extremely challenging. 
1
H and 
13
C NMR signals are 
relatively lower due to the lower relative abundance of these atoms within sulfated molecules as 
well as heterogeneity of molecules. Furthermore, SbO4L represents a polymeric mixture thus 
preventing the presentation of distinct peaks in these techniques. We characterized the final 
product of the synthesis of SbO4L using a combination of techniques such as size exclusion 
chromatography (SEC) HPLC, elemental analysis and reversed-phase ion pairing (RPIP) UPLC-
MS.  
The SEC chromatography is often used for the characterization of hydrophilic polymers. 
It gives an idea of the total size of the polymeric species. SbO4L elutes at 9.62 minutes which 
correlates to an elution volume of 6.74 ml in the method adopted (Figure 17A). A plot of log 
MW vs elution volume of known polystyrene sulfonate standards in the SEC method yields a 
straight line (Figure 17B) which can be used to extrapolate the molecular weight parameters of 
SbO4L. The aqueous SEC-HPLC profile of SbO4L indicated the number (MN), weight (MW) and 
peak (MP) average molecular weights of 9200, 12300, and 9100, respectively, which implied that 
on an average SbO4L chain is ~23 residues long. In comparison, an average UFH chain is 50 
residues long. The SEC chromatograms also indicated that there were no peaks less than 
molecular weight of 1000 Da indicating that the purity of the polymeric species was greater than 
98%. The polydispersity (P), of SbO4L was found to be 1.336, which is similar to that of UFH 
used in the clinic.
200
 The sulfation density calculated on the basis of the difference in MW 
between SbO4L and its unsulfated precursor was ~2 sulfate groups per monomer, which 
compares favorably with that of UFH and LMW heparins (~1.65 negative charges per 
monomer). However, calculation of sulfation using SEC can be exaggerated due to the 
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association of water molecules along with the sulfates. In combination, the uniform β-O4 linkage 
and the high sulfation density of SbO4L suggests a fairly uniform repeating structure in 
comparison to sulfated LMW lignins studied earlier.
182
 
 
Figure 17. Characterizing molecular size of SbO4L. (A) SEC chromatograms for PSS standards, 
monomer ferrulic acid and SbO4L. (B) Plot of log MW vs elution volume of PSS standards yields 
a straight line which can be used to calculate the MP of SbO4L.   
 
Elemental analysis gives useful information about the total elemental composition of the 
molecule, and can be useful in determining purity as well as ratio of functional groups (such as 
sulfates) within a molecule. Elemental analaysis indicates that the sulfation level is closer to 1.25 
sulfate groups per monomer which is less than that of heparin and suggests that SbO4L may 
contain associated waters.  
Further purity and reproducibility of synthesis was confirmed using reversed-phase ion pairing 
UPLC-MS and in vitro thrombin inhibition test for three different batches of synthesized 
polymer. The three batches of SbO4L demonstrated similar UPLC chromatograms in a 
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fingerprint like manner (Figure 18A), while showing identical IC50 for thrombin inhibition (0.20 
± 0.04 μg/ml) (Figure 18B). 
 
Figure 18. Comparison of three different batches of SbO4L using RPIP-UPLC-MS and 
Thrombin Inhibition. (A) Shows the total ion chromatogram (TIC) for the RPIP-UPLC-MS 
performed on three different batches of SbO4L. (B) Thrombin inhibition by three different 
batches of SbO4L shows identical decrease in residual activity of thrombin with an IC50 of 
0.20μg/ml. 
 
SbO4L is a Selective and Potent Inhibitor of Thrombin and Plasmin among the Coagulation 
Enzymes. 
To assess the selectivity of inhibition of SbO4L toward the different coagulation 
proteases, the inhibition of all relevant coagulation enzymes was studied using a chromogenic 
substrate assay in the presence of varying levels of SbO4L, using methods which have been 
adapted previously.
148,151 
The decrease in residual protease activity as SbO4L was varied over 
105-fold was fitted using the dose-response equation 4 to calculate the IC50, hill slope (HS), 
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maximal (YM) and minimal activity (Y0) parameters (Figure 19, Table 2). SbO4L inhibited 
human α-thrombin with an IC50 of 0.17 μg/ml (~18 nM), while fXa and fXIa were inhibited at 
90–500 μg/ml SbO4L (~10–55 μM). In comparison, parent LMW lignins inhibited fXa with IC50 
of 34-120 nM and fXIa with an IC50 of 22-176 nM (Table 1).
186
 Finally, inhibition of FIXa was 
not noticeable at concentrations as high as 81 μg/ml (8.7 μM), while fVIIa–recombinant tissue 
factor (rTF) complex was inhibited 50% at 9.4 μg/ml (1 μM) SbO4L. The only coagulation 
protein that displayed inhibition close to thrombin was plasmin, with an IC50 of 0.38 μg/ml (~40 
nM). However, this is not surprising as the parent lignins were also found to inhibit plasmin in a 
potent, allosteric manner and there seems to be structural resemblance between the heparin 
binding sites of these proteins.
185
 The results indicated that SbO4L inhibited human thrombin 
~20 – 2940-fold better than the closely related coagulation factors. This is a significant 
improvement in selectivity compared to parent chemoenzymatically synthesized lignins (Table 
1). Also, most sulfated GAGs including UFH and fondaparinux do not inhibit these enzymes 
directly at concentrations as high as 100 μg/ml.183  
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Figure 19. Direct inhibition of serine proteases of the coagulation cascade by SbO4L. The 
inhibition of factors IIa (thrombin, fIIa), Xa, XIa, IXa, VIIa, VIIa-tissue factor (TF) complex and 
plasmin by SbO4L was monitored using chromogenic substrate hydrolysis assay. The % residual 
activity of the enzymes was plotted against the log of the concentration to obtain a dose response 
curve which can be fitted to equation 4 to give the IC50, YM, Y0 and HS parameters of inhibition. 
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Table 2. Parameters for sulfated β-O4 lignin (SbO4L) inhibition of coagulation proteases. a 
Protease log [IC50 (g/ml)] IC50 (μg/ml) YM Y0 HS 
Thrombin -6.8  0.1 b 0.17  0.01 99  1 29  1 1.6  0.1 
Factor Xa -3.3  0.6 500  300 100  4 ~1 0.5  0.2 
Factor IXa NI 
c
 NI - 
d 
- - 
Factor XIa -4.1  0.1 89  9 98  3 41  2 1.0  0.2 
Factor VIIa -6.3  0.1 0.54  0.05 103  3 31  3 1.1  0.1 
Factor VIIa – TF ~ -5.0 e >11 e 100  2 ~38 
e
 ~0.5
 e
 
Plasmin -6.4  0.1 0.38  0.04 103  1 31  2 1.1  0.1 
Thrombin w/ AT 
f 
-6.7  0.1 b 0.20  0.01 64  1 6  1 1.9  0.4 
Thrombin/rTM – PC 
g 
-5.4  0.1 4.20  0.08 98  2 3  5 0.96  
0.14 
 
a
The IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct 
inhibition of the protease (see ‘Experimental Methods’ for details). bErrors represent  1 S. D. 
c
No inhibition was observed up to concentrations as high as 81 μg/ml. dNot applicable. 
e
Estimated values. 
f
In the presence of 200 nM AT. 
g
Inhibition of activation of protein C by 
thrombin – thrombomodulin complex. 
 
SbO4L does not Inhibit Other Heparin Binding Serine Proteases 
To assess the selectivity against other heparin-binding serine proteases, we screened 
cathepsin G, human leukocyte elastase, kallikrein, porcine pancreatic elastase, activated protein 
C, plasmin, chymotrypsin, and trypsin, as studied earlier for sulfated LMW lignins.
186
 Except for 
plasmin and factor VIIa, the activity of each protease remained relatively unaffected in the 
presence of 81 μg/ml (8.7 μM) SbO4L (Figure 20) suggesting more than 475-fold selectivity. 
Factor VIIa inhibition by SbO4L does not exist in the physiologically relevant complex with 
tissue factor (TF), suggesting that SbO4L would be a selective inhibitor of plasmin and thrombin 
in the blood.  Thus, SbO4L selectively inhibits human thrombin and plasmin among several 
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structurally similar and relevant trypsin-like proteases. This is a significant improvement in 
selectivity compared to parent LMW lignins which were also found to be potent inhibitors of 
cathepsin G (90-230 nM), HLE (9-17nM), and plasmin (240-1290nM) (Table 1).  
 
Figure 20. SbO4L inhibition of other heparin-binding serine proteases including cathepsin G, 
human leukocyte elastase (HLE), porcine pancreatic elastase (PPE), activated protein C (APC), 
plasmin, chymotrypsin and trypsin at a fixed 81 μg/ml (8.7 μM) (~475-fold excess over the IC50 
of thrombin inhibition). 
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Antithrombin III does not Potentiate SbO4L Mediated Thrombin Inhibition 
Polymeric heparin is a powerful antagonist of thrombin because of its ability to bind 
plasma antithrombin and bridge with thrombin.
201
 In contrast, sulfated LMW lignins were found 
to bind the serpin with reasonable affinity, yet lose direct inhibition potential.
191
 To assess the 
influence of antithrombin on SbO4L activity, direct inhibition of thrombin was studied in the 
presence of 200 nM serpin under otherwise identical conditions. A decrease in thrombin activity 
with increasing SbO4L levels was observed, which was identical to that measured in the absence 
of the serpin, except for the differences in maximal (YM) and minimal (Y0) residual thrombin 
activities (Figure 21, Table 2). The YM and Y0 values decreased by 35% and 23%, respectively, 
due to the reaction of thrombin with antithrombin. However these changes did not affect SbO4L 
inhibition of thrombin (IC50 = 0.2 and 0.17 μg/ml with and without antithrombin, respectively 
(Table 2)). The result implies that antithrombin does not retard or stimulate SbO4L’s inhibitory 
activity. This is a significant point of difference from the parent sulfated LMW lignins, for which 
the serpin-mediated pathway was found to be a competing side reaction.
191
 The results highlight 
an interesting structural aspect that a specific scaffold, i.e., the β-O4-linked scaffold, of the many 
possible in sulfated LMW lignins does not appear to bind the serpin with high affinity, which 
improves mechanistic selectivity.  
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Figure 21. Effect of antithrombin III on SbO4L inhibition of thrombin. Inhibition of thrombin in 
the presence of antithrombin III (w/ AT) with SbO4L (●) was compared to SbO4L alone (○). A 
decrease in YM and Y0 was observed due to direct inhibition of thrombin with antithrombin III. 
However, no change in IC50 was observed. 
 
SbO4L Inhibits Thrombomodulin-Bound Thrombin Less Potently 
Thrombin’s procoagulant activity is highly regulated by cell surface thrombomodulin 
(TM), which transforms it into an anticoagulant protease with specificity for protein C.
15,202
 To 
assess whether TM binding to thrombin alters the activity of SbO4L, we studied the efficacy of 
protein C activation. The level of proteolytically active protein C formed by thrombin–TM 
complex can be measured spectrometrically through hydrolysis of S-2366
193
 following 
suppression of thrombin’s native proteolytic activity using argatroban (~20  Ki)
203
 as its specific 
inhibitor. Measurement of APC levels in the presence of varying SbO4L levels led to a sigmoidal 
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profile on a semi-log plot (Figure 22) suggesting that SbO4L inhibited the protein C activation 
potential of thrombin–TM complex. The IC50 was measured to be 4.2 μg/ml (Table 2), which 
was ~20-fold higher than that measured for SbO4L inhibiting the procoagulant activity of 
thrombin alone. The efficacy of inhibition of protein C activation was found to be nearly 100% 
(Table 2), which is higher than that for thrombin alone (~70%, Table 2). Although the higher 
efficacy may appear to imply that the procoagulation potential of SbO4L is higher than the 
anticoagulant potential, protein C activation is inhibited at 20-times the concentration of 
thrombin inhibition. Thus, the results indicate that SbO4L is a selective inhibitor of the 
procoagulant form of thrombin compared to the anticoagulant form of it. 
 
 
Figure 22. SbO4L inhibition of thrombin-thrombomodulin complex. Inhibition of protein C 
activation potential of thrombomodulin-bound thrombin by SbO4L (○) in comparison to 
thrombin proteolytic activity (□). A shift in the dose response curve to the right by almost 1-log 
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unit shows a change in the potency of almost 20-fold. This is a clear sign that SbO4L can inhibit 
free thrombin with greater potency than thrombomodulin-bound thrombin. 
 
SbO4L Inhibits Different Types of Thrombin in Equivalent Manner 
Small structural differences exist between thrombin structures between different species 
and the degradation products of thrombin. Therefore there is a need to establish SbO4L potency 
against thrombin from different species and γ-thrombin. In order to assess variation of inhibition 
of SbO4L versus different types of thrombin, we screened SbO4L against mouse (murine), cow 
(bovine) thrombin and γ-thrombin (Figure 23). It was found that SbO4L shows little or no inter-
species variation of thrombin inhibition with an IC50 of 0.17 ± 0.03 μg/ml. However, SbO4L 
does show a slight decrease in potency against γ-thrombin with an IC50 of 0.34 ± 0. 03 μg/ml. 
 
Figure 23. Inhibition of different types of thrombin by SbO4L. A comparison of the activity of 
SbO4L against human α-thrombin (□), murine thrombin (Δ), bovine thrombin (○) and human γ-
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thrombin (◊) was performed. It was observed that SbO4L inhibited the different species of 
thrombin with equal potency (IC50 = 0.17 μg/ml), while inhibiting γ-thrombin with 2-fold less 
potent IC50 of 0.34 μg/ml. 
SbO4L Shows Similar Potency Against Thrombin for Fibrinogen Substrate 
Since all ex vivo and in vivo experiments will be close to physiological conditions, we 
thought it would be useful to assess SbO4L inhibition of thrombin using physiologically relevant 
fibrinogen as the substrate. The assay monitors the change in absorbance due to formation of 
fibrin mesh in the presence of SbO4L which is compared to a reaction without the inhibitor to 
obtain the residual activity. A plot of the residual activity as a function of the concentration gives 
a curve similar to those observed with chromogenic substrates and can be fitted to equation 4 
(Figure 24) . The IC50 for SbO4L with fibrinogen at 0.19 ± 0.09μg/ml thus obtained was similar 
to the IC50 with chromogenic substrate at 0.17 ± 0.01μg/ml.  
 
Figure 24. Shows the inhibition of thrombin mediated conversion of fibrinogen to fibrin by 
SbO4L.  
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SbO4L is a Non-Competitive Inhibitor of Thrombin 
To understand the basis of thrombin inhibition, we measured the kinetics of Spectrozyme 
TH hydrolysis at pH 7.4 in the presence of SbO4L. Plots of the initial rates versus substrate 
concentration were hyperbolic, as expected (Figure 25). As the concentration of SbO4L was 
increased from 11.5 ng/ml to 2.3 μg/ml, maximal velocity of hydrolysis, VMAX, decreased in a 
dose dependant manner (Table 3). Fitting the data using the standard Michaelis-Menten equation 
gave an essentially invariant KM,app of 1.5 μM (Table 3). This suggests that SbO4L does not 
affect small molecule chromogenic substrate binding to the active site of thrombin. The VMAX 
decreased from 27.5 to 7.4 mAbsU/min (Figure 25) corresponding to a decrease of more than 
70%. Thus, SbO4L appears to not sterically hinder the interaction of thrombin substrate, but 
brings about changes in the active site that reduce the catalytic rate. This implies that SbO4L is a 
non-competitive, allosteric inhibitor of human thrombin.  
 
Figure 25. Michaelis-Menten kinetics of Spectrozyme TH hydrolysis by thrombin in the presence 
of SbO4L. The initial rate of hydrolysis at various substrate concentrations was measured in a 
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pH 7.4 buffer as described in ‘Experimental Procedures’. The concentrations of SbO4L were 0 
(), 0.012 (), 0.115 (), 0.230 (∆) and 2.3 μg/ml (). Solid lines represent non-linear fits to the 
data using the standard Michaelis-Menten equation. 
Table 3. The Michaelis-Menten Kinetic Parameters of SbO4L Inhibition of Thrombin 
[SbO4L] 
(μg/ml) 
KM 
(µM) 
VMAX 
(mAbsU/min) 
0 1.6  ± 0.2 27.5 ± 0.7 
0.0115 1.7 ± 0.3 20.0 ± 0.1 
0.115 1.3 ± 0.1 14.8 ± 0.1 
0.230 1.5 ± 0.3 11.7 ± 0.5 
2.3 1.4 ± 0.1 7.4 ± 0.1 
 
 
SbO4L does not Compete with Exosite 1 Ligand Hirugen Peptide, but Competes with Exosite 2 
Ligands Heparin and GPIbα  
To assess whether SbO4L engages one or both exosites of thrombin, competitive 
inhibition studies were performed using prototypical ligands, hirugen (exosite 1) and heparin 
(exosite 2). HirP, a hirudin-based dodecapeptide that binds avidly to exosite 1 (KD = 28 nM),
204
 
did not affect the apparent IC50 of thrombin inhibition by SbO4L at concentrations nearly 3.1 
times higher than the affinity (Figure 26, Table 4). This implies that the SbO4L does not engage 
exosite 1 of thrombin. When the thrombin inhibition was studied in the presence of both SbO4L 
and UFH (KD = 15.6 μM, MW = 15,000)
183
, the IC50 increased from 0.2 to 1.25 μg/ml (Figure 
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27A, Table 4), which paralleled that predicted by the Dixon-Webb relationship for ideal 
competitive behavior (Figure 27B). This implied that SbO4L competes with UFH for binding to 
human thrombin, which suggests interaction with residues in or near exosite 2. To further 
understand SbO4L allostery, we decided to utilize recombinant GPIbα (Ki = 100 nM)
80
, which is 
known to bind exosite 2 of thrombin.
52
 Although GPIbα inhibits thrombin-mediated fibrinogen 
to fibrin conversion, it does not affect thrombin’s hydrolysis of small peptides.80 As the 
concentration of GPIbα increases from 0 to 458 nM, the IC50 of SbO4L inhibition of thrombin 
increased from 0.17 to 1.15 μg/ml, which paralleled the predicted values assuming ideal 
competition (Figure 28A and 28B). Thus, SbO4L competes with GPIbα for binding to thrombin. 
This implies that exosite 2 residues that are important for both UFH and GPIbα are likely to be 
important for binding to SbO4L. 
 
Figure 26. Effect of exosite-1 binding competitor hirudin-based peptide (HirP) on the inhibition 
of thrombin by SbO4L. The inhibition of human α-thrombin was studied through Spectrozyme 
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TH hydrolysis assay at pH 7.4 in the presence of fixed concentrations of the competitor HirP. 
Solid lines represent dose-response curves formed by fitting the data points to equation 4.  
 
Figure 27. Effect of exosite-2 binding competitor unfractionated heparin (UFH) on the 
inhibition of thrombin by SbO4L. (A) The inhibition of human α-thrombin was studied through 
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Spectrozyme TH hydrolysis assay at pH 7.4 in the presence of fixed concentrations of the 
competitor porcine UFH. Solid lines represent dose-response curves formed by fitting the data 
points to equation 4 to yield the IC50 at various concentrations of the competitor. (B) Analysis of 
ideality of competition between SbO4L and porcine UFH. A comparison between the observed 
IC50 (in black) and those calculated using the Dixon-Webb relationship (Eq. 6) (in grey) at 
different concentrations of UFH (0-100 μM) demonstrates that porcine UFH competes 
effectively against SbO4L thereby causing an increase in IC50 which is comparable to the 
predicted IC50 for ideal competition. 
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Figure 28. Effect of exosite-2 binding ligand GPIbα on the inhibition of thrombin by SbO4L. (A) 
The inhibition of human α-thrombin was studied through Spectrozyme TH hydrolysis assay at pH 
7.4 in the presence of fixed concentrations of the competitor GPIbα. Solid lines represent dose-
response curves formed by fitting the data points to equation 4 to yield the IC50 at various 
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concentrations of the competitor. (B) Analysis of ideality of competition between SbO4L and 
GPIbα. A comparison between the observed IC50 (in black) and those calculated using the 
Dixon-Webb relationship (Eq. 6) (in grey) at different concentrations of GPIbα (0, 229 and 458 
nM) demonstrates that GPIbα competes effectively against SbO4L thereby causing an increase 
in IC50 which is comparable to the predicted IC50 for ideal competition. 
 
Table 4. Inhibition parameters of human α-thrombin by SbO4L in the presence of exosite 1 
(HirP) and exosite 2 (UFH and GPIbα) ligands. 
 IC50 
(μg/ml)a 
YM Y0 HS 
[HirP] nM     
0 0.15  0.01b 102  14 24  1 1.2  0.1 
8.6 0.17  0.02 103  2 23  1 1.2  0.1 
86 0.14  0.02 102  3 17  2 1.2  0.2 
[UFH] μM     
0.2 0.22  0.01 99  1 26  1 1.6  0.1 
2.0 0.34  0.02 98  1 26  1 1.8  0.1 
20 0.66  0.05 96  1 24  1 1.6  0.2 
100 1.25  0.14 100  1 28  2 0.9  0.1 
[GPIbα] nM     
0 0.23 ± 0.01 101 ± 2 18 ± 1 1.5 ± 0.1 
229 0.69 ± 0.05 99 ± 1 22 ± 1 1.5 ± 0.1 
458 1.15 ± 0.05 101 ± 2 28 ± 1 1.6 ± 0.1 
 
a
The IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct 
inhibition of human α-thrombin. bErrors represent  1 S. E. 
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SbO4L Mediates Thrombin Inhibition via Binding to Arg233, Lys235 and Lys236 residues on 
Exosite 2. 
To pinpoint the exosite 2 residues that interact with SbO4L, we studied 11 recombinant 
thrombins containing substitution of basic residues with alanine. These single- or multi-site 
thrombin mutants have been shown earlier to possess fully functional catalytic machinery.
190,205
 
Alanine replacement at either Arg126, Arg165, Lys169, Arg173, Arg175, or Lys240 showed 
minimal change (0.9 – 2.1-fold) in SbO4L inhibitory potential as compared to their wild-type 
recombinant reference (Figure 29A, Table 5). Likewise, a triple mutant containing 
Arg93,101,107Ala did not affect the IC50. However, single-site alanine substitution at Arg233, 
Lys235, and Lys236 positions was found to have 8 – 9-fold increase in IC50 as compared that for 
the wild-type thrombin indicating that each of these residues are important for SbO4L-mediated 
inhibition of thrombin (Figure 29A and 29B, Table 5). Interestingly, these residues are also 
known to be crucial for interaction with heparin
206
 and GPIbα52,116,117. 
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Table 5. Inhibition parameters of SbO4L for different thrombin exosite 2 mutants in 
comparison to wild type recombinant protein.  
Thrombin 
Enzyme 
IC50 
(μg/ml)a 
YM Y0 HS 
WT 0.34  0.03b 102  3 14  1 1.5  0.2 
Triple Mutant 0.52  0.07 101  3 32  2 1.4  0.3 
R126A 0.67  0.04 101  1 18  1 1.3  0.1 
R165A 0.41  0.06 100  3 33  2 1.3  0.2 
K169A 0.55  0.02 101  1 15  1 1.6  0.1 
R173A 0.32  0.04 103  2 35  1 1.2  0.1 
R175A 0.66  0.03 102  1 25  1 1.2  0.1 
R233A 3.2  0.1 99  1 16  1 1.4  0.1 
K235A 2.8  0.2 100  1 17  1 1.4  0.1 
K236A 2.8  0.2 97  1 16  1 1.3  0.1 
K240A 0.73  0.02 99  1 22  1 1.5  0.1 
a
The IC50, HS, YM, YO values were obtained following non-linear regression analysis of direct 
inhibition of human α-thrombin. bErrors represent  1 S. E. 
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Figure 29. Effect of SbO4L on Thrombin Mutants (A) Shows a comparison of SbO4L inhibition 
of mutant vs wild type (WT) for the different thrombin mutants which included a triple mutant 
(Tpl Mut) R93,97,101A, R126A, R165A, K169A, R173A, R175A, R233A, K235A, K236A and 
K240A. (B) Shows the representative dose response curves for SbO4L inhibition for recombinant 
thrombin mutants R233A, K235A and K236A in comparison to wild type (WT) thrombin. 
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SbO4L Causes Allosteric Change in Active Site that restricts Quenching by Acrylamide 
To check accessibility of the active site upon SbO4L binding, quenching studies were 
carried out on fFPR-Thrombin using the collisional quencher- acrylamide. Collisional quenching 
occurs when the fluorophore comes in contact with the quenching agent in the excited state. If 
the binding of SbO4L causes a dramatic conformation change within the active site, the active 
site fluorescein of fFPR-Thrombin would be less accessible to quenching by the collisional 
quencher acrylamide. We observed that SbO4L bound fFPR-Thrombin was more resistant to 
collisional quenching compared to fFPR-Thrombin alone (Figure 30A). Upon treating the data 
thus obtained in the Stern-Volmer relationship we noticed that the Stern-Volmer relationship 
fitted well with a linear relationship (Figure 30B), indicating one type of fluorophore present 
both with and without inhibitor. The quenching constant (KSV) obtained from the slope, was 
almost 80% lower in the presence of SbO4L, suggesting that the conformational change induced 
restricts the accessibility of the quenching agent by a great extent. This is a clear indication of a 
dramatic change in the active site conformation due to SbO4L binding to thrombin.   
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Figure 30. Active site fluorescence quenching in presence of SbO4L (A) The fluorescence 
intensity of fFPR-Thrombin was monitored with and without SbO4L at various concentrations of 
collisional quencher acrylamide. It was observed that the enzyme active site fluorescein was 
more susceptible to quenching in the absence of SbO4L compared to in its presence. Further, 
there was a recovery of fluorescence (shown in grey arrow) when SbO4L was added to the 
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enzyme alone after addition of final concentration of acrylamide. (B) Stern-Volmer plots further 
showed that there was approximately 80% reduction in the quenching constant in the presence of 
SbO4L suggesting that the fluorophore was less accessible for quenching. 
 
SbO4L binds Exosite 2 with Approximately Five Ionic Interactions 
Exosite 2 binding ligands are in general highly ionic in nature. To learn about the ionic 
contributions of SbO4L while binding to thrombin we performed salt dependence binding 
affinity studies. The affinity was measured by monitoring the change in fluorescence of active-
site labeled fFPR-Thrombin in titrations with SbO4L. It was observed that as the concentration 
of salt increased, the binding affinity of SbO4L for thrombin decreased (Figure 31A, Table 6). A 
plot of the log of the dissociation constant as a function of log of the salt concentration yielded a 
straight line (Figure 31B) with a R
2
 of 0.98, whose slope gave the Γsalt value of -5.0 (Equation 
9). This is comparable to other exosite 2 binding ligands such as reported values of GPIbα and 
Heparin (Table 7). Γsalt values can roughly indicate that there are 5 ionic interactions occurring 
between SbO4L and thrombin. This combined with the sulfation level of approximately 1-2 
sulfates per monomer indicates that the active binding portion of SbO4L could be limited to a 
simple dimeric-pentameric lignin molecule.  
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Figure 31. Effect of salt on SbO4L binding to thrombin. (A) Decrease in fluorescence intensity 
was observed as fFPR-Thrombin was titrated with SbO4L at various concentrations of sodium 
chloride. The change in fluorescence calculated as a ratio to the initial fluorescence was plotted 
against the concentration of SbO4L and fitted to the quadratic equation to obtain the 
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dissociation constant under the various conditions. (B) A linear relationship of log KD vs Log 
[NaCl] for SbO4L interaction with thrombin yields an R
2
 of 0.98. The slope of the line provides 
information on the Γsalt which indicates that there are approximately 5 ionic interactions 
involved between SbO4L and thrombin.  
Table 6. Dissociation Constant of SbO4L at various concentrations of NaCl. The 100mM 
KD is comparable to the IC50 obtained as the IC50 experiment is performed at similar salt 
concentration. 
NaCl (mM)  KD (μM)  
100  0.02  0.01  
125  0.12  0.02  
150  0.17  0.03  
200  0.89  0.06  
 
Table 7. A comparison of the Γsalt values of SbO4L to various thrombin binding ligands 
from literature. It can be seen that SbO4L shows comparable salt interactions to exosite 2 
binding ligands as compared to exosite 1 binding ligands. 
Ligand Γsalt (NaCl) 
Hirugen -1.06 ± 0.02
207
 
Thrombomodulin ± Chondroitin Sulfate -4.8 ± 0.6
207
 
Thrombomodulin – Chondroitin Sulfate -2.2 ± 0.4207 
Glycocalicin (Soluble GPIbα) -4.2 ± 0.279  
 
-4.6  0.4208  
Heparin  -4.8 0.6 209 
SbO4L  -5.0  0.2  
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Thrombin Inhibition by SbO4L can be Reversed by Protamine 
A major advantage of heparin therapy is its amenability to protamine-based reversal. It is 
also one of the reasons why fondaparinux continues to suffer because its iatrogenic bleeding is 
difficult to reverse rapidly. To test whether SbO4L inhibition of thrombin can be reversed, we 
studied the recovery of thrombin activity following successive introduction of protamine. Figure 
32 shows the thrombin recovery profile with varying levels of protamine after achieving 50% 
inhibition with SbO4L. The protamine-mediated recovery profile essentially mirrors the SbO4L-
induced inhibition profile. More importantly, the level of recovery is quantitative at high enough 
protamine concentrations. Further, the recovery was instantaneous as no extended incubation 
was necessary to observe reversal. The concentration of protamine necessary to recover 50% 
thrombin activity, i.e., RC50, could be calculated using an equation similar to the logistic 
equation 4 used for inhibition studies and found to be ~0.1 μg/ml, a concentration equivalent to 
the IC50 for SbO4L inhibition of thrombin. 
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Figure 32. Protamine-mediated reversal of SbO4L inhibition of thrombin. Recovery of thrombin 
activity at varying levels of protamine following 50% inhibition by SbO4L was measured 
through the Spectrozyme TH hydrolysis assay at pH 7.4. Solid line represents non-linear fit of 
the data by a logistic function similar to equation 4 to obtain the RC50, the concentration of 
protamine necessary to recover 50% thrombin activity. 
 
3.4 Discussion 
Current anticoagulation therapy largely involves heparin, heparin derivatives and vitamin 
K antagonists. While being inexpensive, such therapies suffer from complications such as 
bleeding and heparin-induced thrombocytopenia arising due to their non-selectivity in activity.
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Alternative small molecule inhibitors of coagulation enzymes such as dabigatran against 
thrombin and rivaroxaban against factor Xa have also been proposed for therapy. But such 
treatments still have bleeding complications and safety concerns over long term use and are 
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expensive in comparison to heparins.
211,212
 The ideal anticoagulant when compared to these 
would therefore have to be highly selective, with little or no side-effects, while also being 
inexpensive.  
 Thrombin, being a central enzyme in the coagulation cascade, would seem to be an ideal 
target for preventing coagulation. Yet due to its plastic nature, active site inhibitors of the 
enzyme have been unable to protect the haemostatic system from bleeding risks, and therapies 
targeting thrombin require frequent monitoring. On the other hand, targeting thrombin’s 
allosteric exosites in a manner similar to nature could potentially lead to a better anticoagulant 
for clinical purposes.
213
  
 The design for a homogenous direct thrombin inhibitor which acts on thrombin via 
allosteric mechanisms has originated in the form of sulfated low molecular weight lignins.
183
 
Originally, such sulfated lignins were designed to mimic heparin.
182
 However, heparin is devoid 
of any direct inhibition of thrombin, i.e. it requires antithrombin to inhibit thrombin. In contrast 
these sulfated lignins were found to inhibit thrombin by targeting exosite 2 without any need of 
serpin.
183
 Hence the mechanism of such parent lignins was unique and not comparable to any 
natural ligand. Additionally, such chemoenzymatically synthesized lignins were complex 
heterogeneous mixtures with respect to their inter-monomeric linkages. As a result, these 
polymers were not selective for a single enzyme and were found to be active against a number of 
other heparin binding serine proteases (Table 1).
185,186
 The predominant inter monomeric linkage 
found in such lignins is generally β-O4 type. Thus the idea arose that a chemically synthesized 
homogenous lignin polymer with the β-O4 type inter-monomeric linkage would possibly be 
more selective and potent as a thrombin inhibitor. The synthesis of such a molecule could further 
provide insight into the novelty of the mechanism. 
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We synthesized SbO4L using simple 7-step protocol with readily available and 
inexpensive starting materials. The β-O4 lignin polymer can be synthesized easily in two steps 
from the monomer 5. To generate sufficient quantities of SbO4L for all studies, the key 
intermediate 5 was produced in larger quantities using a new 4-step, mild synthetic route which 
can be utilized in the future for creating modifications.
196,197
 Polymerization of monomer 5 
followed by reduction gave purified β-O4 lignin using methods described before.198,199 
Ultimately, the sulfation of the lignin so synthesized yielded SbO4L. The SbO4L so produced 
was characterized utilizing elemental analysis and SEC, while batch-to-batch reproducibility of 
the synthesis to produce biosimilars was established using RPIP-UPLC-MS fingerprinting and 
thrombin inhibition assay. Overall, the synthetic procedure yielded highly reproducibly active 
SbO4L which can be scaled up for the most part. 
SbO4L was found to inhibit thrombin and plasmin with high potency and selectivity over 
other serine proteases. Such selectivity is remarkable when compared to previous 
chemoenzymatically synthesized lignins (Table 1). While inhibition of plasmin may seem to 
thwart the anticoagulant potential of SbO4L, free plasmin is not normally present in blood and is 
often neutralized by α2-antiplasmin and α2-macroglobulin, which ensures buildup of plasmin for 
antifibrinolytic activity takes several hours.
214,215
 As a result the antifibrinolytic effect of SbO4L 
may not be observed if it successfully prevents clot formation in the first place. Moreover, 
SbO4L might be capable of providing better prophylactic anticoagulation by preventing the 
fibrinolysis of already formed clots, thereby preventing bleeding but simultaneously preventing 
new clot formation. Clinically, this dual mechanism of anticoagulation and plasmin inhibition by 
SbO4L could prove useful in disseminated intravascular coagulation (DIC) which can be caused 
by sepsis, surgery or trauma, cancer and complications during pregnancy or childbirth.
185,216,217
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DIC manifests when there is widespread clotting due to thrombin mediated coagulation and 
paradoxical bleeding due to plasmin mediated fibrinolysis.  
Mechanistically SbO4L was found to inhibit thrombin without the help of antithrombin 
III. While addition of antithrombin III does not result in an increased potency, it does increase 
the efficacy (indicated by the decrease in YM and Y0 values) of SbO4L mediated thrombin 
inhibition. These results suggest an independent mechanism of SbO4L and antithrombin against 
thrombin. In comparison parent LMW lignins showed increased potency in the presence of 
antithrombin III.
191
 Thus SbO4L is mechanistically more selective than parent lignins. 
Since thrombin plays vital anticoagulant functions by binding to thrombomodulin, we 
investigated if SbO4L abrogates such antithrombotic action by testing it against thrombomodulin 
thrombin complex for physiological substrate activated protein C. Our results indicated clearly 
that SbO4L is a more potent inhibitor of free thrombin compared to the anticoagulant form of 
thrombin. Thus SbO4L could be used to shift the population of thrombin in the blood from a net 
procoagulant state to thrombomodulin bound anticoagulant state. Furthermore, combining 
SbO4L with thrombomodulin as a therapy for DIC could prove very useful in management of the 
coagulopathy. 
SbO4L inhibits a variety of types of thrombin from different species as well as thrombin 
degradation products in an equipotent manner. This is important because significant structural 
differences exist between different types of thrombin among species and thrombin degradation 
products. For example, in place of Asp222 in the sodium binding site, murine thrombin has a 
Lys222 which results in a charge reversal substitution in the Na+ binding loop.
218
 This allows the 
Nζ atom of the Lys222 of murine thrombin to mimic the positive charge of the Na+ and mimic 
the cation, thereby locking the enzyme in a “fast-form” which is also believed to be the 
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procoagulant form. SbO4L’s equipotent inhibition of murine thrombin is a sign that the molecule 
is capable of inhibiting the fast-form of thrombin. This is also important from a translational 
point of view to show that SbO4L based inhibition can possibly be tested in mouse thrombosis 
models. Bovine thrombin on the other hand shows differences in the Tyr-Pro-Pro-Trp segment of 
the 60-loop, Glu-192 and catalytic residues His57 and Ser195.
219
 SbO4L inhibition of bovine 
thrombin further confirms that the molecule possibly binds at the more conserved exosite 2 
rather than the structurally different active site when compared to human thrombin. Human γ-
thrombin is a degradation product of human α-thrombin in which the exosite 1 is disordered.220 
As a result of this γ-thrombin has a disrupted capability for cleaving physiological substrate 
fibrinogen to form a clot.
221
 SbO4L shows potent inhibition of γ-thrombin, albeit with 2-fold 
lower activity. This was important from future translational research in establishing SbO4L 
antiplatelet activity. SbO4L was also found to inhibit thrombin while using fibrinogen as a 
substrate with comparable potency to the chromogenic substrates. This is fundamental for 
development of any anticoagulant to ultimately be useful with physiologically relevant 
substrates.  
The mechanism by which SbO4L inhibits thrombin was deduced by an amalgamation of 
Michaelis-Menten kinetics, competition and mutagenesis studies. Michaelis-Menten kinetics data 
showed that SbO4L inhibition is non-competitive with chromogenic substrate and is therefore 
binding at an allosteric site – away from the active site of the enzyme. Binding of SbO4L was 
found to induce allosteric change in the active site conformation as was confirmed using 
collisional quenching.  
Competition with known exosite 2 ligands unfractionated heparin (UFH) and GPIbα and 
exosite 1 ligand hirugen peptide further help locate SbO4L binding at exosite 2 of thrombin. 
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Using specific single and triple mutants of exosite 2 basic residues, it was concluded that SbO4L 
requires Arg233, Lys235 and Lys236 of thrombin exosite 2 for binding. These residues are 
known to be vital for the interaction of sulfated tyrosine-rich anionic peptide (STRAP) of GPIbα, 
a platelet surface glycoprotein, with thrombin.
79,115-118
 Structurally this STRAP resembles the 
aromatic-sulfate strategy observed in SbO4L and hence it can be imagined that the binding sites 
of the two molecules are overlapping. Mechanistically, it is known that GPIbα can inhibit 
thrombin’s fibrin formation activity via binding to exosite II, which is comparable to SbO4L.79,80 
However, this site of thrombin has never been explored previously from a potential drug-
targeting perspective.  
Characterizing the binding nature of SbO4L to thrombin, using a salt dependant study of 
binding affinity helped in identifying that the nature of the interactions has a high ionic 
component similar to other known exosite 2 ligands (Table 8). This study indicated that 
approximately 5 sulfate groups were involved in the binding of SbO4L to thrombin. This result 
when taken together with the elemental and size exclusion chromatography data, suggests that 
the actual pharmacophore moiety of SbO4L may be a simple dimeric-pentameric lignin 
molecule. 
Lastly, we have demonstrated the possibility of reversing SbO4L activity using FDA 
approved protamine in an in vitro assay. From a therapeutic point of view, these results suggest 
that an antidote for SbO4L is already present in the market. Hence establishing safety windows 
should be easier knowing that the antidote is at hand.  
Overall, we have shown a significant step forward from parent LMW lignins in terms of 
homogeneity, ease and reproducibility of synthesis, potency and selectivity with the development 
of SbO4L. Furthermore, we have been able to compare the mechanism of SbO4L with an 
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endogenous ligand in the form of GPIbα. Our in vitro studies have helped us identify a potential 
pathway to develop smaller and more homogenous molecules to target the GPIbα site by 
mimicking SbO4L. However, further validation of targeting this site was required in higher order 
assays such as in plasma, whole blood and even in vivo. 
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Chapter 4: Advanced Level Characterization of Antithrombotic Potential of SbO4L 
4.1 Introduction 
 Annually, more than 100 publications present data on thrombin inhibitors, yet only a 
small percentage of the publications involve new chemistry.
3
 The majority of small molecules 
out of these target the active site of thrombin. This trend is gradually changing as allosteric 
inhibitors are gaining more importance. Targeting the active site results in complete knockout of 
the enzyme and hence results in complicated clinical outcomes. As a result there is a large 
amount of research being performed on determining the efficacy, pharmacology, toxicology and 
clinical outcomes of thrombin inhibitors.  
 SbO4L, a completely synthetic sulfated β-O4 lignin, was found to be a potent and 
selective inhibitor of thrombin when tested in vitro. We established that the mechanism involved 
in SbO4L mediated anticoagulation was unique in that it mimicked the platelet receptor GPIbα. 
Similar to GPIbα, SbO4L is known to reduce the catalytic efficiency of thrombin towards 
fibrinogen cleavage by binding to exosite 2 of thrombin.
79
 Competition and mutagenesis data 
highlighted the fact that the binding site was identical to the GPIbα-STRAP. Physiologically 
thrombin binding to GPIbα is vital for procoagulant platelet aggregation and activation 
functions.
81,222
  
For any new mechanism of anticoagulation to be clinically relevant, it has to translate 
well from in vitro assays to ex vivo and finally to in vivo tests. Therefore, it is vital for us to 
106 
 
establish that targeting the GPIbα site on thrombin by SbO4L could yield a potentially useful 
antithrombotic, which is effective even in vivo. Additionally, we reasoned that the fact that 
SbO4L could compete and mimic GPIbα for binding to thrombin may result in dual 
pharmacological actions in ex vivo and in vivo systems. We hypothesized that SbO4L could 
possibly act as antithrombotic using a dual mechanism, wherein, (a) it could provide an allosteric 
direct inhibition of thrombin to produce anticoagulant activity; and (b) it could compete with 
GPIbα from binding to thrombin and thereby producing antiplatelet activity as well (Figure 33). 
 
Figure 33. Dual mechanism of antithrombotic action by SbO4L in advanced assays. Thrombin is 
capable of cleaving fibrinogen using its active site, and binding to GPIbα using its exosite 2. 
Binding of GPIbα to exosite 2 causes an allosteric change within the active site. SbO4L binding 
to thrombin at exosite 2 in a manner similar to GPIbα could possibly induce allosteric inhibition 
of thrombin towards catalytic conversion of fibrinogen resulting in anticoagulant activity, while 
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also providing a competitive inhibition of thrombin binding to GPIbα resulting in antiplatelet 
activity. 
 
To verify if our hypothesis of dual mechanism holds true in complex systems, we first 
tested the anticoagulant and antiplatelet activities separately in plasma and platelet rich plasma 
using APTT/PT assays and platelet aggregation/activation assays respectively. We then sought to 
investigate the properties of this dual mechanism in tandem by using whole blood with 
Hemostatic Analysis System and Thromboelastography tests. Finally we tested if SbO4L could 
provide sufficient antithrombotic effect in vivo in several mouse thrombosis models. 
 
4.2 Experimental Procedures 
Materials 
Pooled normal human plasma for coagulation assays was purchased from Valley Biomedical 
(Winchester, VA). Activated partial thromboplastin time (APTT) reagent containing ellagic acid, 
thromboplastin-D and 25 mM CaCl2 were obtained from Fisher Diagnostics (Middletown, VA). 
Thromboelastograph® Coagulation Analyzer 5000 (TEG®), disposable cups and pins, and 200 
mM stock CaCl2 were obtained from Haemoscope Corporation (Niles, IL). All other chemicals 
were analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher 
(Pittsburgh, PA) and used without further purification. 
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Plasma APTT/PT Assay 
Clotting times were determined in a standard 1-stage recalcification assay with a BBL 
Fibrosystem fibrometer (Becton-Dickinson, Sparles, MD), as reported previously.
183,184
 For 
prothrombin time (PT) assays, 10 µl of SbO4L (or a reference agent) was mixed with 90 μl of 
citrated human plasma, incubated for 30 s at 37°C, followed by the addition of 200 µl of pre-
warmed thromboplastin. For activated partial thromboplastin time (APTT) assays, 10 µl of 
SbO4L solution was mixed with 90 µl citrated human plasma and 100 µl 0.2% ellagic acid. 
Clotting was initiated by adding 100 µl of 25 mM CaCl2. Each experiment was performed in 
duplicate. The averaged data was plotted and a quadratic trend line was used to calculate the 
concentration of SbO4L that doubles the clotting time (2×APTT or 2×PT). 
 
Effect of Serum Albumin on the Inhibition Efficacy of SbO4L 
The effect of serum albumin on SbO4L inhibition of thrombin was tested by assessing residual 
thrombin activity in 20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 8000, pH 7.4, 
containing BSA at four different concentrations (0, 1, 2.5 and 10 mg/ml). Briefly, 5 μl of 2.3 
mg/ml SbO4L was incubated with 185 μl of each of these buffers in a 96-well plate at 37°C in 
duplicate. To this was added 5 μl of 240 nM thrombin, incubated for 10 minutes and 5 μl of 5 
mM Spectrozyme TH added to measure the residual active thrombin.  
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Preparation of Platelet Rich and Platelet Poor Plasma 
Whole human blood was collected from healthy volunteers and used to prepare platelet rich 
plasma (PRP) by spinning at 70 x g for 10 minutes and platelet poor plasma (PPP) by spinning at 
900 x g for 10 minutes. The platelet count in the PRP was adjusted to 220,000 platelets / ml 
using the PPP and the material was used within 4 hours of withdrawal. 
 
Platelet Aggregation Assay 
The effects of SbO4L on γ-thrombin induced platelet aggregation were studied using the 
Chrono-log Model 700 Optical Lumi-Aggregometer (Chrono-Log Corporation, Havertown, PA). 
Briefly, 250 μl of PRP was incubated with SbO4L (0-535 μg/ml) for 3 minutes at 37°C. 
Aggregation was initiated by using either 152nM or 76nM of γ-thrombin. Aggregation was 
monitored using the optical settings of the aggregometer for at least 6 minutes. 
 
ATP Secretion Assay 
The effects of SbO4L on α-thrombin mediated ATP secretion were studied using the Chrono-log 
Model 700 Optical Lumi-Aggregometer (Chrono-Log Corporation, Havertown, PA) following 
manufacturers protocol with slight modification. Briefly 450 μl of PRP was incubated with 50μl 
of CHRONO-LUME reagent containing Luciferase enzyme and 0-5μl SbO4L (0-248 μg/ml final 
concentration in the cuvette) for 3 minutes at 37°C. One unit of CHRONO-PAR thrombin (α-
thrombin) was added to the solution and the luminescence was monitored for at least 6 minutes. 
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An ATP standard of 2 nmoles was run separately in similar conditions to standardize the 
luminescence and obtain quantitative results of the amount of ATP released in each run. 
 
Haemostatic Analysis System 
Analysis of platelet function and clot structure was performed using the HASTM from 
Hemodyne, Inc., Richmond, VA, as reported earlier.
184
 A mixture of 700 μl of citrated whole 
blood and 10 μl SbO4L (or water as control) was co-incubated at room temperature for 5 minutes 
and then placed in a disposable cup. To initiate clotting, 50 μl of 150 mM CaCl2 was added. As 
the clotting proceeds, platelets attach to surfaces generating tension within the fibrin meshwork 
from which platelet contractile force (PCF) and clot elastic modulus (CEM) parameters are 
obtained in an automated manner. 
 
Thromboelastography TEG

 Analysis of Clot Formation 
TEG

 assays were performed as reported earlier.
184
 Briefly, the assays were initiated by 
transferring 20 μl of 200 mM CaCl2 into the Haemoscope
TM
 disposable cup, oscillating through 
4°45’ angle at 0.1 Hz, followed by the addition of a mixture of 340 μl of sodium citrated whole 
blood containing 10 μl SbO4L or water (control) at 37°C. This recalcification initiates clot 
formation in the TEG

 coagulation analyzer, which operates until all data collection (R, K, α and 
MA) is computed in an automated manner. 
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In Vivo FeCl3 Carotid Artery Thrombosis Model 
Procedures involving mice were approved by the Institutional Animal Care and Use Committee 
of Vanderbilt University and have been previously reported.
223,224
 Wild type C57Bl/6 mice were 
anesthetized with 50 mg/kg IP pentobarbital. SbO4L (0, 100, 300, 500 or 1000 μg in 100 μl 
phosphate buffered saline) was infused into the right internal jugular vein. Five minutes after 
infusion, the right common carotid artery was exposed and fitted with a Doppler flow probe 
(Model 0.5 VB, Transonic System, Ithaca, NY). Thrombus formation was induced by applying 
two 1 x 1.5 mm filter papers (GB003, Schleicher & Schuell, Keene, NH) saturated with FeCl3 
(3.5% solution) to opposite sides of the artery for three min. After washing the site of injury with 
PBS, flow was monitored for 30 min. Mice were sacrificed by pentobarbital overdose after 
conclusion of the experiment, while under anesthesia. 
 
In Vivo Rose-Bengal Laser Thrombosis Model 
In vivo testing using Rose Bengal thrombosis model was adapted from previously reported 
literature.
224
 C57Bl/6 mice were anesthetized as above and 500 μg of SbO4L in 100 μl phosphate 
buffered saline was infused into the right internal jugular vein. Five minutes after infusion, Rose 
Bengal (75mg/kg) was infused through the internal jugular vein, and the carotid artery was 
illuminated with a 1.5 mW 540 nm laser (Melles Griot, Carlsbad, CA) positioned 6 cm from the 
artery. Flow was monitored for 120 min. Mice were sacrificed by pentobarbital overdose after 
conclusion of the experiment, while under anesthesia. 
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Tail Bleeding Time 
Tail bleeding assays offer a measure of hemostasis in the presence of SbO4L. To perform the tail 
bleeding assay, the mice are anesthetized as mentioned above, following which the animal is 
placed on a 37 °C heating pad. 100 μl SbO4L is then injected into a lateral vein using a 1 ml 
tuberculin syringe fitted with a 27-gauge needle. The tail is trasected with a scalpel just above 
the tip. The bleeding tail is immersed in a centrifuge tube filled with PBS and kept at 37 °C. The 
animal is observed for up to 1000 seconds and the time required to cease the bleeding is noted. 
Mice are sacrificed prior to recovering from bleeding. 
 
4.3 Results 
SbO4L Prolongs Clot Formation in Plasma APTT/PT Assays 
Prothrombin (PT) and activated partial thromboplastin times (APTT) are traditional 
measures of the anticoagulation state of human plasma. Figure 34 shows the variation in plasma 
PT and APTT in the presence of SbO4L. A significant concentration-dependent prolongation of 
clotting times was observed suggesting good anticoagulation potential. A 2-fold increase in PT 
required 68 μg/ml of SbO4L, corresponding to 7.5 μM, which is significantly lower than that 
needed for a generic LMWH (142 μg/ml, 31.6 μM) and a clinically used LMWH (enoxaparin, 
339 μg/ml or 75 μM).184 Likewise, a two-fold increase in APTT required 20 μg/ml (2.2 μM) of 
SbO4L, which compares favorably with a concentration of 5.9 μg/ml (1.3 μM) for generic 
LMWH in inducing plasma anticoagulation. 
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Figure 34. Prolongation of clotting time as a function of SbO4L concentration in either the 
prothrombin time (PT) or the activated partial thromboplastin time (APTT) assay. The solid lines 
are trend lines, and not exponential fits.  
 
SbO4L Inhibition of Thrombin is Abrogated in the Presence of Albumin 
Despite this high potency (comparable to enoxaparin), SbO4L displays a loss of ~100–
340-fold in potency in human plasma from that in in vitro enzyme systems. To assess the basis 
for this difference, we studied the effect of serum albumin on the effectiveness of SbO4L. Figure 
35 shows the change in relative thrombin activity in the presence of fixed concentration of 
SbO4L and varying concentrations of bovine serum albumin (BSA), a surrogate for its human 
counterpart. In the absence of BSA, thrombin’s hydrolytic activity was 22% ([SbO4L] = 0.42 
μg/ml), which was found to increase to 56, 59 and 72% in the presence of 1, 2.5 and 10 mg/dl 
BSA, respectively. This suggests that the presence of BSA results in a significant drop in 
inhibitor potency probably arising from non-specific sequestering of SbO4L. Interestingly, a 
0
30
60
90
120
150
0 30 60 90 120
APTT
PT
C
lo
tt
in
g 
Ti
m
e
(s
)
[SbO4L] (mg/ml)
114 
 
maximal thrombin activity of ~75% is reached suggesting that some SbO4L remains free, and 
therefore inhibitory, at high enough plasma albumin concentration.  
 
Figure 35. The effect of serum albumin on the thrombin inhibition potential of SbO4L. Solid line 
to the data represents a rectangular hyperbolic fit to the data to derive the maximal thrombin 
activity at limiting concentrations of BSA. The dotted line represents the maximal thrombin 
activity. See text for details. 
 
SbO4L Potently Inhibits Platelet Aggregation in Platelet Rich Plasma (PRP) 
The idea that targeting GPIbα could also be utilized to prevent platelet aggregation and 
activation for antithrombotic potential has been around.
159
 Since SbO4L binds to identical 
binding site as GPIbα and competes with it, we tested the effects our molecule had on thrombin 
mediated platelet aggregation. An optical method to monitor platelet aggregation was used which 
0
20
40
60
80
100
0 2 4 6 8 10 12
%
 R
e
si
d
u
al
 
Th
ro
m
b
in
 A
ct
iv
it
y
[Serum Albumin]    (mg/dL)
115 
 
employs an increase in transmittance of platelet rich plasma (PRP) as a signal for aggregation 
under high sheer. The use of γ-thrombin was done so as to monitor purely platelet aggregation 
activity without interference by fibrin mesh formation (Figure 36).
123
 Two different test 
concentrations of γ-thrombin were used as the trigger and it was noticed that as the concentration 
of the activating thrombin was lowered from 152 nM and 76 nM (Figure 37A and 37B 
respectively), the amount of SbO4L required to prevent platelet aggregation was also reduced 
from 321 μg/ml to 105 μg/ml. Furthermore at all doses of SbO4L, a unique platelet response was 
observed in which the platelets would initiate aggregation no matter how high the concentration 
of SbO4L, but after reaching its peak aggregation would start showing a reduced 
transmittance(Figure 37C). This could be a result of change of shape of the platelets or 
disaggregation. 
 
Figure 36. A comparison of α-thrombin and γ-thrombin as platelet aggregation initiators. α-
thrombin causes the formation of a fibrin mesh which traps the platelet aggregates. In 
comparison, γ-thrombin creates aggregates without any formation of fibrin network. The last 
α-thrombin γ-thrombin γ- thrombin + SbO4L
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image shows that in the presence of SbO4L, γ-thrombin is incapable of forming platelet 
aggregatres. 
 
Figure 37. Variation in level of platelet aggregation as a function of the concentration of 
SbO4L. Platelet aggregation was measured in the presence of varying concentrations of SbO4L 
using either 152 nM (A) or 76 nM (B) γ-thrombin as the trigger. Representative traces (C) of 
human platelet rich plasma (PRP) aggregation induced by 76 nM γ-thrombin in the presence or 
absence of 217 μg/mL SbO4L. Aggregation was monitored by following time dependence of 
transmittance at 620 nm following addition of γ-thrombin.  
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SbO4L Potently Prevents ATP Secretion by Platelets in PRP 
To assess platelet activation, ATP secretion was monitored using luminescence method 
of monitoring ATP release by using luciferase enzyme under high sheer. Use of α-thrombin was 
possible in this assay due to the fact that fluorescence detections were independent of fibrin 
formation. It was observed that 248 μg/ml of SbO4L potently inhibited ATP release by 85% 
when 1 unit of α-thrombin was used to trigger platelet activation (Figure 38), and a dose 
dependant increase in ATP release was observed with decrease in SbO4L. 
 
Figure 38. Reduction in the level of ATP released by platelets in the presence of varying levels of 
SbO4L. ATP release by platelets was monitored using luminescence in the presence of luciferase 
enzyme.  
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SbO4L Inhibits Platelet Prothrombotic Function in Whole Blood when Analyzed using  
Hemostasis Analysis System (HAS) 
To further assess the whole blood anticoagulant potential of SbO4L, we utilized HAS™, 
which evaluates platelet contribution to clot formation (Figure 39).
184
 This technique evaluates 
clot structure through the measurement of clot elastic modulus (CEM), which is the ratio of 
stress induced by platelets to strain arising from the change in clot thickness. The technique also 
provides information on contractile forces between platelets, i.e., the platelet contractile force 
(PCF), that adhere to surfaces and restrict relative movement of two cups. PCF depends on the 
platelet number, their metabolic status, presence of thrombin inhibitors and degree of GPIIb/IIIa 
exposure.
225
 On the other hand, CEM depends on the clot micro-structure, fibrinogen 
concentration, and thrombin formation rate. It has been suggested that PCF and CEM changes 
can be correlated with susceptibility to bleeding and/or thrombotic tendency. 
SbO4L affects PCF and CEM in a dose-dependent manner (Table 8). As the 
concentration of SbO4L increases from 0 to 74 μg/ml, the PCF and CEM decrease from 8.0 to 
0.7 kDynes and 18.3 to 0.6 kDynes/cm
2
, respectively (Figure 39A and 39B, Table 8). When 
comparisons are made with enoxaparin, strikingly similar results are observed except for the 
range of concentration used for the clinically used anticoagulant. Whereas PCF value of 0.7 was 
achieved at 74 μg/ml (8.1 μM) for SbO4L, it was achieved at 2.0 μg/ml (444 nM) for enoxaparin 
suggesting a ~37-fold better potency for the latter on weight basis and ~18-fold better potency on 
molar basis. These results further confirm that SbO4L mediated targeting of the GPIbα site of 
thrombin exosite II could be useful in creating future antithrombotics. 
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Figure 39. Comparison of the effect of SbO4L on platelet function in whole blood using 
hemostasis analysis system (HAS™). (A) and (B) show the change in platelet contractile force 
(PCF) and clot elastic modulus (CEM), respectively, with time at various fixed concentrations of 
SbO4L (0–74 μg/ml). 
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Table 8. Hemostasis Analysis System Parameters for SbO4L Anticoagulation in 
Comparison to Enoxaparin. 
 
 
Hemostasis Analysis
* 
 
[Conc] 
(μg/ml) 
TOT
*
 
(min) 
PCF
* 
(kDynes) 
CEM
* 
(kDynes/cm
2
) 
     
SbO4L 0 6.3 8.0 18.3 
 0.07 5.1 7.3 12.0 
 7.4 6.6 5.8 6.3 
 37 11.3 3.3 3.9 
 74 13.6 0.7 0.6 
     
Enoxaparin 0 3.6 7.6 21.6 
 0.7 5.2 5.3 15.1 
 1.0 9.1 3.6 12.7 
 1.6 11.0 2.8 8.5 
 2.0 12.5 0.9 2.9 
*Analysis was performed using Hemostasis Analysis System (HAS) on human whole blood as 
described in ‘Experimental Procedures’. Parameters deduced from this analysis included TOT 
(thrombin onset time), PCF (platelet contractile force) and CEM (clot elastic modulus).  
 
SbO4L Inhibits Thrombus Formation in Whole Blood when Analyzed using 
Thromboelastography (TEG) 
To evaluate SbO4L as an anticoagulant in whole blood, we employed TEG
®
, which is 
quite often used to monitor anticoagulation therapy with LMWH.
184
 TEG

 assesses the nature of 
physical forces within a clot, which are dramatically affected by the presence of an anticoagulant 
in blood. In a nutshell, the clot formation in TEG

 is recorded as a force transduced on a pin at 
the center of a blood-containing cup. Several parameters are evaluated from this force 
measurement including maximum amplitude (MA), the shear elastic modulus (G), the reaction 
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time (R) and the angle α. MA and G are measures of clot stiffness, while R and α are measures of 
the rate of clotting. Figure 40 shows the output obtained from the instrument. 
Table 9 shows the change in R, α, MA and G parameters as a function of the 
concentration of SbO4L. Briefly, as the concentration of SbO4L increases from 0 to 152 μg/ml, 
R increases from 7.7 to 25.9 min, while α decreases from 56° for normal blood to 22° indicating 
that the kinetics of fibrin polymerization and network formation is significantly depressed by the 
presence of SbO4L. Enoxaparin behaves in a similar manner, except that its effective 
concentrations range from 1–5 μg/ml. Likewise, SbO4L reduces MA and G in a manner similar 
to enoxaparin (Table 10), except for the ~30-fold better potency of the latter (~15-fold molar 
basis). 
 
Figure 40. Effect of SbO4L on whole blood hemostasis using Thromboelastography (TEG). 
Insert on the right shows different parameters obtained from TEG study. SbO4L shows a dose 
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dependant change in clotting parameters MA, R, α and G, with a doubling in clot initiation time 
(R) at 76.5 μg/ml. 
 
Table 9. Thromboelastography Parameters for SbO4L Anticoagulation in Comparison to 
Enoxaparin 
 Thromboelastography
*
 
 [Conc] 
(μg/ml) 
R
*
  
(min) 
α*  
(degs) 
MA
*
 
(mm) 
G
* 
(kDynes/cm
2
) 
      
SbO4L 0 7.7 56.0 61.0 7821 
 0.15 8.9 50.5 50.5 7658 
 15.2 13.2 42.5 57.0 6628 
 76.5 16.9 43.0 55.5 6236 
 152 25.9 22.0 41.5 3547 
      
Enoxaparin 0 7.0 59.0 56.5 6457 
 1.35 8.0 49.0 51.0 5204 
 2.7 11.5 43.0 47.0 4434 
 3.4 14.0 41.0 46.0 4260 
 4.5 17.0 31.5 42.0 3621 
*Analysis was performed using thromboelastography (TEG) on human whole blood as described 
in ‘Experimental Procedures’. Parameters deduced from this analysis included R (time to clot 
initiation), α (angle), MA (maximum amplitude) and G (shear elastic modulus).  
 
SbO4L shows potent Antithrombotic Action in FeCl3 Thrombosis Model, Rose Bengal Laser 
Injury Model and Tail-Bleeding Time In Vivo in Mice 
The antithrombotic effect of SbO4L was tested in two well-characterized arterial 
thrombosis models following procedures previously reported.
223,224
 Exposure of the carotid 
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artery of wild type mice to a 3.5% solution of FeCl3 results in formation of an occlusive platelet-
rich thrombus within 15 minute (Figure 41A). SbO4L prevented occlusion of the arteries of 
some mice at doses of 250 or 500 mg, with all mice protected from vessel occlusion at a dose of 
1000 mg (Figure 41A and 41B). FeCl3 is thought to produce a severe injury accompanied by 
desquamation of vascular endothelium.  
The effects of a 500 mg dose of SbO4L were also tested in a model in which vessel injury 
is produced by exposure to laser light after infusion of the dye Rose Bengal. The carotid artery is 
surgically made accessible and the laser light is shined upon it. The laser light converts the dye to 
free radicals, which result in vessel occlusion with a platelet-rich thrombus in 44.7  6.5 minutes 
in vehicle treated controls. Occlusion occurred in 76  21.3 minutes in animals treated with 500 
μg SbO4L.  
The effective dose of SbO4L that prevented thrombosis in the FeCl3 model (1000 μg), 
also caused a marked prolongation of the tail bleeding time, from ~110 s to > 1000 s. The total 
blood loss was also higher from 50 μl to 120 μl. 
Note- This work was performed by the Dr. David Gailani Laboratory (Vanderbilt University 
Medical Center, Nashville, TN) 
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Figure 41. In vivo anticoagulant effect of SbO4L as observed in C57BL/6 mice. (A) 
Measurement of arterial blood flow using Doppler flow probe, as a representation of the 
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formation of occlusive platelet-rich thrombus in the carotid artery of mice with the application of 
3.5% FeCl3 with a prior injection of either 100 or 1000 μg of SbO4L. (B) Dose-dependent 
decrease in arterial clot formation in a study with 4-8 C57BL/6 mice shows that SbO4L is most 
effective at a dose of 1000 μg. 
 
4.4 Discussion 
 In order to test if the in vitro efficacy holds true ex vivo and in vivo, we put SbO4L 
through an array of assays in ascending order of complexity. Furthermore, such assays helped in 
characterizing the dual mechanism of antithrombosis demonstrated by SbO4L, which is truly 
unique in comparison to any known molecule.  
 First, to test the anticoagulant activity, SbO4L was tested in classical APTT and PT 
assays which are standard assays often used to test anticoagulant drugs.
226,227
 SbO4L was found 
to double the clotting times in both the assays 20 and 68 μg/ml concentrations, which was 
comparable to clinically approved LMWH Enoxaparin. More importantly since there is only a 3-
fold difference between 2xAPTT and 2xPT values, suggesting that in advanced systems, SbO4L 
is possibly inhibiting the common pathway of coagulation involving thrombin alone, with little 
side reaction more with the intrinsic pathway. These results agree well with the screening 
information obtained from the in vitro tests. Interestingly, prolonging the APTT rather than PT 
might be vital to prevent thrombosis and thromboembolism.
228
 Hence SbO4L selectivity of effect 
on APTT over PT might be a boon to the molecule’s safety profile. 
 When the quantitative numbers of the APTT and PT are compared to the in vitro results, 
there is a remarkable drop in activity (~ 100 fold). The most likely explanation is that SbO4L 
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binds to albumin in the plasma. Albumin is the most abundant carrier protein present within the 
blood and is known to bind almost all drugs. We successfully demonstrated that SbO4L’s in vitro 
inhibition of thrombin is in fact lowered by the presence of serum albumin. The most interesting 
fact was that even at high concentrations of serum albumin, SbO4L retained some thrombin 
inhibitory potential. Thus it is possible that albumin binding of SbO4L might reduce the efficacy 
but not completely eliminate it. Additionally, this binding might extend the duration of SbO4L 
action as albumin binding may prove a useful reservoir for SbO4L. 
 To test our second hypothesis that SbO4L could possibly inhibit thrombin-mediated 
platelet aggregation and activation by competing with GPIbα, we performed extensive platelet 
aggregation and activation studies in platelet rich plasma (PRP). Platelet aggregation studied by 
light transmission and activation studied by ATP secretion using luminescence are well 
standardized tests used to test antiplatelet agents.
229,230
 We found that SbO4L was a good 
antiplatelet agent at low concentrations. These results when taken together with the competition 
data, support the fact that SbO4L’s competition with GPIbα could potentially abrogate thrombin-
mediated platelet aggregation. When given in vivo, it is highly probable that both mechanisms, 
i.e., anticoagulation and antiplatelet, play a role. Further, our studies showed that the amount of 
SbO4L required to thwart the platelet aggregation was related to the amount of the triggering 
agent used. This could be an important observation, which might affect dosing regimens in future 
studies. 
 SbO4L was then tested in whole blood using HAS and TEG. Whole blood is a system in 
which both coagulation and platelets play a role. While the HAS system tests the platelet 
functions more closely, TEG is useful to look at the coagulation parameters. Both systems are 
often used to monitor and test anticoagulant and antiplatelet therapy clinically.
229-231
 In both, the 
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HAS and TEG studies, SbO4L showed good potency comparable to the concentrations used in 
the plasma and PRP assays. Furthermore, in both assays SbO4L’s potency was comparable to 
clinically used enoxaparin, suggesting that SbO4L’s antithrombotic potential could be useful. 
 The ultimate test to check for SbO4L’s efficacy was performed using two in vivo arterial 
thrombosis models. The FeCl3 mouse arterial thrombosis model has been used since 1944 to 
stimulate thrombosis, and is widely used to test the efficacy of anticoagulant and antiplatelet 
therapies.
232
 SbO4L was found to be effective at dose of 1 mg i.v. bolus and showed a dose 
dependant efficacy. However, the FeCl3 induced thrombosis is a severe injury cause by an 
“outside-in” mechanism on the vessel walls, which is unlike what is observed in pathological 
clotting.
233
 We therefore also analyzed the efficacy of SbO4L using laser induced arterial 
thrombosis model which is physiologically more similar to what is observed in thrombotic 
disorders where the clotting occurs without damage to the vessel wall. We found SbO4L 
effective at doses of even 500 μg i.v. which is comparable to all the ex vivo data that we have 
obtained. 
 To assess the effect of SbO4L on hemostatic function, we tested the effect of the 
molecule on the tail bleeding time in mice. The effective dose of SbO4L in the FeCl3 model 
(1000 μg) did show a prolonged tail-bleeding time and total blood loss compared to controls. 
However, this is not surprising given the molecule’s dual mechanism of action. It is known that 
patients suffering from Bernard Soulier syndrome, who show defective expression of GPIb-IX-V 
complex, demonstrate such phenotype as well.
234
 Furthermore, bleeding models only provide 
information about hemostasis in response to specific type of injury, and will not necessarily 
reflect the propensity to bleed, especially when the injury involves other body parts. 
Additionally, it is possible that the bleeding issues could be arising from the fact that SbO4L is 
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still a mixture and possibly has off-site effects elsewhere. Therefore, future smaller, homogenous 
derivatives of SbO4L would need to be tested in more in vitro, ex vivo and animal models in 
order to establish efficacy, safety and bleeding risks. 
 Overall, we have established that ex vivo and in vivo, SbO4L can act via a dual 
mechanism of anticoagulation and antiplatelet action. Furthermore, such activity gives SbO4L 
antithrombotic potential similar to LMWH which is clinically used. Thus targeting the GPIbα 
site with more homogenous small molecules may prove to be a useful means of producing newer 
antithrombotic drugs, but may require some more testing to establish safety with respect to 
bleeding.  
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Chapter 5: Identifying Novel Lignin Based Inhibitors and Mechanisms for Factor XIa 
5.1 Introduction 
 As discussed in chapter 1, factor XIa (fXIa) is emerging as a useful target for 
prophylactic treatments of hyper-thrombotic states.
145
 It is believed that developing novel 
inhibitors of factor XIa could possibly prevent thrombosis, while not causing bleeding side 
effects. Furthermore, an allosteric inhibitor of factor XIa could possibly fine tune this control 
further.  
It has been reported that the allosteric inhibition of fXIa can be brought about by large 
molecules with highly charged polyanions such as dextran sulfate, heparin, hypersulfated 
heparin, sulfated pentagalloyl glucoside (SPGG) and sulfated quinazolin-4(3H)-ones 
(QAOs).
192,194,235
 Although a number of active site inhibitors have been reported, there has been 
only one report on allosteric small-molecule inhibitors (<1000 Da) of fXIa.
235
 These are the 
sulfated QAOs, that demonstrated a maximum potency of only 52 μM. This leaves room for 
more potent small-molecule allosteric inhibitors for fXIa to be discovered. The sulfated QAOs 
were found to bind near the heparin binding site (HBS). Sulfated QAOs are expected to display 
poor bioavailability owing to their large size and high charge density. Finally, no inhibitor of 
factor XIa has been approved for use as anticoagulant in the clinic.  
 Chemo-enzymatically synthesized LMW lignins were found to be potent inhibitors of 
factor XIa with IC50 ranging from 22-176 nM (Table 1). Such lignins presented diversity in their 
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inter-monomeric, linkage which resulted in lack of selectivity and were found to be potent 
inhibitors of other serine proteases as well. Hence, it was necessary to fish-out structural 
components from these mixtures with selective activity for specific target serine proteases. 
Interestingly, the chemically synthesized SbO4L, which has only the β-O4 type inter-monomeric 
linkage was found not to be a potent inhibitor of factor XIa (IC50 = 89 μg/ml or 9.6 μM). This 
suggested that it is possible that some other scaffold within the chemoenzymatic LMW lignins 
was more potent towards factor XIa (Figure 42).  
 
Figure 42. Rationale for screening sulfated small molecule library to identify factor XIa 
selective inhibitor. Synthetic SbO4L, which was designed from chemo-enzymatic lignins provided 
selective thrombin and plasmin inhibition. Therefore, it could be possible that other scaffolds 
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from the parent lignins have high selectivity for other enzymes for which the chemo-enzymatic 
lignins showed good potency. One such enzyme of interest is factor XIa. We therefore wanted to 
explore possibilities for finding a factor XIa selective inhibitor through library screening of 
sulfated small molecules enriched in the β-5 type linkage mimetics in the form of the benzofuran 
molecules. 
 
 In order to find such a selective inhibitor lead molecule, the Desai Lab decided to screen 
a library of sulfated aromatic small molecules that have been previously synthesized in our 
laboratory. A library of 65 molecules (Figure 43) was tested based on various scaffolds including 
sulfated flavonoids,
236-240
 sulfated tetrahydro-isoquinoline,
241-243
 sulfated quinazolinone,
235
 
sulfated benzofurans,
187-189
 and other sulfated small molecules.
242,244
 As a group, the library 
consisted of at least 12 different scaffolds allowing for a diverse range of structures to be 
profiled. In particular, this library was enriched in the benzofuran scaffold, which is expected to 
mimic the β-5 type linkage found in lignins and therefore explore the possibility of finding new 
lignin based inhibitors of factor XIa.
187-189
 Our initial screen, followed by defined inhibition 
profiles identified a number of benzofuran dimers and trimers with potent inhibition of factor 
XIa (Table 10). In particular, molecule 24 showed highest potency at sub-micromolar 
concentrations (IC50 = 0.82 μM) and was 8-fold more selective for factor XIa over thrombin 
(IC50 = 5.8 μM).
189
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Figure 43. Library of sulfated small molecules (SSMs). 
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Table 10. Inhibition Parameters of Sulfated Small Molecules (SSMs) against factor XIa. 
SSM No. IC50 (μM)* YM* Y0* HS* 
15 9.7 ± 0.3 102±2 4±4 6.9±1.2 
21 7.5 ± 0.6 95±3 0±2 1.9±0.3 
23 14.9 ± 0.3 94±1 7±1 5.2±0.4 
24 0.82 ± 0.02 99±2 0±1 3.8±0.3 
25 47.2 ± 0.9 99±2 3±2 6.6±0.8 
27 6.4 ± 0.1 99±2 2±1 11.7±1.5 
28 29.9 ± 0.8 103±2 10±2 6.4±0.9 
29 384 ± 38 98±4 0±1 1.9±0.4 
30 29.9 ± 0.5 100±2 3±2 6.9±0.7 
32 99 ± 13 101±5 0±1 1.3±0.2 
61 109 ± 2 96±1 0±1 6.2±0.5 
63 122  ± 3 98±2 0±1 6.0±0.9 
* Error bars represent ± 1 S.E. 
**Work reported in Argade, M; MS Thesis, Titled: Discovery and biophysical characterization 
of allosteric inhibitors of factor XIa (FXIa). (2012). 
 
 
 The affinity for 24 was found to be similar to the IC50 with a KD of 1.2 ± 0.3 μM (data 
not shown). Michaelis-Menten kinetics data indicated that 24 inhibits factor XIa by binding away 
from the active site (Figure 44A). To localize the binding site of 24 on factor XIa, we tried 
competition with heparin. We expected there to be good competition with heparin due to the fact 
that 24 is a derivative of chemoenzymatic lignins, which are known to bind at heparin binding 
site of factor XIa, and the fact that it is sulfated. However, to our surprise we found no direct 
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competition of 24 with heparin (Figure 44B). To date, no allosteric factor XIa inhibitor was 
developed which was incapable of competing with heparin. This fact led us to believe that 
compound 24 and its congeners were possibly binding at a novel site, and inducing factor XIa 
inhibition by a truly unique mechanism. 
Note- The screening, inhibition and allostery was determined with the help of a fellow graduate 
student Ms. Malaika D. Argade and have been reported earlier in her master’s thesis. Title: 
Discovery and biophysical characterization of allosteric inhibitors of factor XIa (FXIa). (2012). 
We therefore pursued the identification of the binding site utilizing molecular modeling. 
We confirmed these results by explaining the activities of congeners of 24 and characterizing the 
inhibition of 24 with the catalytic domain alone. Lastly, we tested if the binding of 24 to factor 
XIa could possibly convert the enzyme back into a zymogen-like conformation. 
135 
 
 
Figure 44. Compound 24 inhibits factor XIa by allosteric mechanism. (A) Michaelis-Menten 
Kinetics of substrate S-2366 hydrolysis in the presence of inhibitor 24 from 0-900 nM. A clear 
change in VMAX from 77.4 ± 1.7 to 9.8 ± 0.5 was observed, with relatively no change in KM (0.32 
± 0.06 mM), which is characteristic of non-competitive inhibition. (B) Competition of inhibition 
of factor XIa by 24 in the presence of varying concentrations of porcine UFH from 0-16 μM. It 
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can be seen that there is essentially no change in IC50 even in the presence of 16 μM UFH, which 
indicates that 24 inhibits factor XIa allosterically at a site away from the heparin binding site. 
  
5.2 Experimental Procedures 
Materials 
The recombinant catalytic domain and wild-type full length factor XIa were gifts from Dr. 
Alireza Rezaie (Saint Louis University, MO). Dansyl-EGR labeled factor XIa (dEGR-fXIa) was 
obtained from Haematologic Technologies (Essex Junction, VT). All other chemicals were 
analytical reagent grade from either Sigma Chemicals (St. Louis, MO) or Fisher (Pittsburgh, PA) 
and used without further purification. 
 
fXIa Structure Model Generation 
Since no crystal structure exists for the activated form of factor XIa, a model for the complete 
fXIa was created by replacing the inactive catalytic domain of the zymogen form (PDB id: 2f83) 
with the activated catalytic domain crystal structure available (PDB id: 1zom) using Pymol.
245
 
Further, hydrogens were added to the chimera protein and minimized keeping all heavy atoms as 
aggregates using Tripos Sybyl-X v.2.1 [www.tripos.com/sybyl]. 
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Docking of Compound 24 
An in silico localization of the possible binding sites for compound 24 was performed using 
simple docking protocols. Briefly, the most active compound, 24, was modeled in SybylX 2.1 
[www.tripos.com/sybyl] and docked into the structure of the chimera at 8 sites. These sites were 
defined as being within 24 Å around residues Lys8, Arg136, Gln153, Lys252, Lys325, Lys357, 
Asn566, and Arg584 as shown in Figure 45A. For each site, 1000 genetic algorithm runs were 
employed without allowing early termination. Automatic cavity detection was permitted. Docked 
poses were scored using GOLDSCORE and only the top two poses were retained. Triplicate 
docking runs were employed to ensure the docked poses were reproducible giving us a total of 6 
docked poses per site. No constraints were employed because this was an exploratory docking 
simulation. Average RMSD across the docked poses was ascertained using in-house code 
utilizing the Openeye OEChem toolkit.
246
  
 
Inhibition of Catalytic Domain of Factor XIa 
The inhibition of molecule 24 was tested against the catalytic domain of factor XIa alone using a 
microplate assay similar to the one described above. Briefly, in each well 85 µL of buffer (0.05M 
Tris, 0.15M NaCl, 0.1% PEG-8000, 0.02% Tween-80 at pH=7.4) was taken, to which was added 
5 µL of enzyme fXIa (final concentration of 0.765 nM in each well). Serial dilutions of the 
inhibitor stock with decrements of 2/3
rd
 were incubated with the enzyme by addition of 5 μL of 
stock inhibitor solutions. The mixture was then incubated for 10 minutes and throughout the 
experiment the temperature was maintained at 37°C. After incubation, 5 µL of substrate S-2366 
(final concentration of 330 µM) was added to each well and the initial velocities of the reaction 
were determined by measuring the absorbance of p-nitroaniline at 405nm released due to 
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substrate cleavage by fXIa. The initial rate of substrate hydrolysis was treated using equation 4 
and a nonlinear curve fitting was performed to give the IC50 values. 
 
Effect on Protein Anisotropy in Presence of 24 using Perrin Plot    
Monitoring protein anisotropy at variable temperatures or viscosities can demonstrate change in 
the hydrodynamic radius of the protein. Briefly, in a 96-well microplate, 33 μl of water along 
with 5 μl of tris-HCl buffer (to give final concentrations of 50mM tris-HCl and 150mM NaCl 
pH=7.4) was added. To this, 20 μl of dansyl-EGR labelled factor XIa (dEGR-fXIa) was added 
(final concentration of enzyme was 0.81μM) along with 2 μl of either solvent or 1mM of 
compound 24. The wells were read using the FlexStation III, (Molecular Devices, Sunnyvale, 
CA) polarization module. The exciation and emission wavelengths were set at 340 nm and 530 
nm, respectively. The plate was incubated at various temperatures ranging from 22-40°C for 10 
minutes before reading the plate for the parallel (I∥) and perpendicular (I⊥) intensities of 
fluorescent light. The average of 13 readings was taken and the anisotropy (r) calculated using 
the classical equation.
247
  
   
 ∥    
 ∥    
  (Eq. 10) 
The viscosity (η) of the solution at various temperatures (T) was obtained using a calculator 
based on previous literature.
248,249
 A plot of the reciprocal of anisotropy (1/r) versus the T/η 
yields a straight line which fits the Perrin equation
247
: 
 
 
 
 
  
 
   
    
  (Eq. 11) 
where, r0 is the fundamental anisotropy of the fluorophore in the absence of diffusion, τ is the 
fluorescence lifetime of the fluorophore, R is the gas constant, V is the hydrodynamic volume of 
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the protein to which the fluorophore is attached, T is the temperature and η is the viscosity of the 
solution. When fit to the equation of a straight line y = mx + c, where y= 1/r, c = 1/r0 and m = 
τRT/Vr0. The ratio of the slopes of the lines corrected for the r0, give the ratio of the 
hydrodynamic volumes in the presence and absence of the inhibitor. 
 
5.3 Results 
Preparation of a Knowledge-Based Model for Full-Length Factor XIa 
Molecular modeling has been used previously to predict binding mode of benzofuran 
oligomers to thrombin exosite 2.
189
 We therefore hypothesized that similar docking studies could 
be used to identify the binding site of 24 within factor XIa. However, docking studies require the 
existence of a crystal structure of the target protein. To date, there is no complete crystal 
structure of full length factor XIa with its four apple domains. The crystal structures of full-
length zymogen form of factor XIa, i.e. factor XI,
124
 and the catalytic domain of factor XIa
250
 are 
available. This gave us an opportunity to create a model chimera full length factor XIa by simple 
replacement of the inactive catalytic domain of the zymogen with the active structure (Figure 
45A). Such a model would be physiologically relevant as the protein would be presented in its 
zymogen-like inactive state.  
Docking Suggests Probable Binding Pose for Benzofuran Trimers 
The binding site of benzofuran trimers on fXIa is, as of yet, unknown. We conducted 
computational studies to predict the same. Eight areas on the protein surface displayed a 
relatively higher positive charge density, and were stochastically nominated as possible binding 
sites for 24. The residue approximately at the center of the positively charged patch was 
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identified (Figure 45A) and all residues within 24 Å around of it were defined as the binding site. 
This covered practically the entire protein surface, ensuring exhaustive exploration during 
identification of possible binding sites. The small molecule was then docked into all 8 sites 
exhaustively. Any sites where 24 could interact reproducibly would be a plausible binding site. 
Five out of 6 docked poses of 24 displayed a very low RMSD (1.6 Å) near Lys252 
displayed a very low RMSD (Figure 45B). Moreover, this reproducible pose rationalized the 
observed SAR of the benzofuran trimers quite well (Figure 45B, C and D). The lone sulfate of 
the trimers present on ring A is required for activity because it forms strong interactions with 
Lys255. Note- although the docking center was Lys252, the molecule seemed to localize near 
Lys255 near it. When this sulfate is removed in compounds 29, this vital interaction cannot be 
formed, resulting in ≈400 fold loss of activity (IC50 = 384 μM). The 6-ethoxy position of the 
benzofuran A of the trimer occupies a shallow hydrophobic pocket, where an ethyl group 
displayed optimal van der Waal’s interactions. While a methyl group was tolerated here (as in 
compound 23 with IC50 = 14.9 μM and 27 with IC50 = 6.4 μM), an isopropyl group displayed 
reduced activity because of steric hindrance, as observed in compounds 25 (IC50 = 47μM). 
Finally, a negative charge density at the 3-position of the benzofuran C on the trimer, as present 
in compounds 29 and 30, was not tolerated because the hydrophobic nature of the binding pocket 
and the presence of Glu567 near the trimer.  
Interestingly, this binding site is on the A3 domain of fXIa, which is also known to 
possess a heparin-binding site (HBS).
131,132
 Even though compound 24 is sulfated, it binds 
adjacent to the HBS, which explains why we did not observe competitive binding with heparin. 
While heparin does cause some inhibition of factor XIa activity (~30% with an IC50 ~ 220nM), it 
cannot completely inhibit the enzyme compared to 24, indicating that the site of 24 is unique in 
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its mechanism and away from the heparin binding site. The strong correlation with 
experimentally observed SAR and biophysical studies constitutes conclusive evidence that we 
have successfully identified the binding site for these benzofuran trimers on fXIa. 
 
Figure 45. Modeling studies for inhibitor 24. (A)A chimera model was created using the 
catalytic domain crystal structure (PDB i.d.: 1zom) and the heavy chain from the zymogen 
Arg584
Arg136
Lys357 Lys8
Asn566
Gln153
Lys252
Lys325
A C
B
D
A
B
C
142 
 
crystal structure (PDB i.d.: 2f83). Compound 24 was docked into 8 loci around residues Lys8, 
Arg136, Arg184, Lys252, Lys325, Lys357, Asn566, and Arg584,, shown as blue spheres. (B) The 
structure docked reproducibly at a site located near residue Lys252, as witnessed by a low 
RMSD between the docked poses. (C) Surface features of the site where 24 docked reproducibly, 
shows that the sulfate group of 24 interacts well with Lys255. (D) A cartoon representation the 
best docked pose of 24 near Lys252 with the interactions highlighted with the binding pocket and 
the benzofurans A, B and C. The panels C and D explains the SAR observed. Lys255 interacts 
favorably with the sulfate group of 24 – removing the latter eradicates activity. Ethyl groups at 
6-ethoxy position of benzofuran A of the benzofuran trimers are ideal for van der Waal’s 
contacts with the protein, producing optimum activity. Methyl groups are also tolerated here 
because they are smaller, but isopropyl groups reduce activity because the trimers can no longer 
fit. Presence of a carboxylate at 3-position of benzofuran C of the trimers is not tolerated due to 
the presence of a hydrophobic pocket and two acidic residues (Glu202 and Glu227) which repel 
the compounds with acidic functionality here. 
 
Inhibition of Factor XIa by 24 is Apple-Domain Driven 
In order to check if the inhibition of factor XIa by 24 is apple domain driven, we tested 
24 against the catalytic domain of factor XIa (fXIa-CD) (Figure 46). It was observed that the 
IC50 of 24 against fXIa was 1.2 ± 0.2 μM, while that for fXIa-CD was 49 ± 2 μM, indicating that 
without the heavy chain of fXIa there is almost a 40-fold reduction in potency. 
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Figure 46. Loss in inhibition potency of 24 upon removal of the Apple domains containing the 
putative site of binding. Inhibitor 24 shows a 40-fold higher IC50 against the catalytic domain of 
factor XIa (, fXIa-CD) in comparion to that against the wild-type fXIa (□). 
 
Inhibition of Factor XIa by 24 Causes a Dramatic Conformational Change in Protein Structure 
As the temperature increases, the rotational correlation time (θ) of the protein decreases 
due to increased motion. This causes a decrease in anisotropy. The rotational correlation time of 
the protein is direct function of the hydrodynamic volume of the protein.
247
 However, to monitor 
such changes, the fluorescence lifetime (τ) of the fluorophore must be comparable to the 
rotational correlation time of the protein.
251
 Hence, we used dansyl labeled factor XIa, as dansyl 
has a relatively long fluorescence lifetime.
252
 We used a Perrin plot (Figure 47) in order to 
identify any dramatic changes in the hydrodynamic volume of the protein due to inhibitor 
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binding. When fit to the Perrin equation, dEGR-factor XIa gave a best fit line having an 
equation:  
y = 10.61x10
-6
x+4.05 (R
2
 = 0.988), 
while in the presence of the inhibitor the equation changed to:  
y = 7.50x10
-6
x + 4.46 (R
2
 = 0.979).  
The reciprocal of the intercept would yield fundamental anisotropy of the fluorophore in 
the absence of diffusion (i.e. c=1/r0). This means that in ideal conditions the intercept should 
have identical values. However, in practice, fluorophores display segmental motions, which are 
independent of overall diffusion when bound to proteins.
247
 Binding of the inhibitor has been 
shown to cause conformational changes within the active site which could affect such segmental 
motions and hence there is a small variation between the intercepts of the two plots. When the r0 
is corrected for within the slope of the line, the ratio of the slopes would yield the ratio of the 
hydrodynamic volumes as all other values are constant under the conditions of the experiment: 
 
 
 
 
         
 
 
 
             
 
             
          
    (Eq. 12) 
The ratio of the corrected slopes (m/c) is 1.55 ± 0.06 suggesting that when 24 binds to 
fXIa, it causes a 55 ± 6% increase in the hydrodynamic volume of the protein. Such an increase 
would be indicative of a dramatic conformational change within the protein. 
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Figure 47. Binding of 24 to factor XIa induces a large conformational change. A Perrin-plot for 
dansylated factor XIa (dEGR-fXIa) in the absence (□) and presence (▲) of 24 showing a 
significant difference in slope indicating considerably different hydrodynamic volumes of factor 
XIa alone and in complex with 24. 
 
5.4 Discussion 
Development of inhibitors targeting upstream processes of the coagulation cascade is 
gradually gaining speed in order to obtain drugs with fewer side-effects.
140
 Active site inhibitors 
of factor XIa have been synthesized recently (within the last 10 years) but often are either 
irreversible by forming a covalent bond with Ser195 or have a strongly basic group to identify 
the Asp189 in the S1 pocket of serine proteases.
250,253-258
 Both these methods of inhibition lead to 
lack of selectivity as these features are present on most, if not all, serine proteases.  
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Previously synthesized QAOs offered a novel pathway of discovering small-molecule 
allosteric inhibition of factor XIa by targeting hydrophobic domains adjacent to heparin-binding 
sites.
235
 They do so by initial coulombic attraction of anionic parts of the ligand (sulfate groups) 
to the cationic heparin binding site of fXIa, followed by formation of a tight lock with an 
adjacent hydrophobic patch. Although the potency of these molecules was relatively low, with 
the lowest IC50 of only 52μM, the study provided impetus to search for a more potent allosteric 
inhibitor using similar rationale of coulombic-attraction followed by inhibition using sulfated 
small molecule. 
Chemo-enzymatically synthesized LMW lignins were found to be potent inhibitors of 
factor XIa (Table 1). Yet they suffered from lack of selectivity due to their heterogeneity in their 
intermonomeric linkage. Furthermore, SbO4L was found to not have factor XIa inhibitory 
potential, suggesting that the lignin factor XIa inhibitory activity possibly arose from other 
scaffolds than the β-O4 type lignins. 
Our library screen of 65 SSMs took upon the challenge of finding smaller or more potent 
analogs, which could possibly inhibit fXIa via allosteric mechanisms. We have successfully 
identified at least 8 molecules (Table 10) with an IC50 lower (greater potency) than previously 
reported QAOs against fXIa. Furthermore, the predominant class of inhibitors was identified as 
the benzofuran dimers and trimers, which are close mimics of the β-5 type linkage found in 
lignins.
188
 The most potent trimer 24 was 50-fold more active than the most active QAO. Trimer 
24 was shown to be an allosteric inhibitor of factor XIa, but was surprisingly not competitive 
with heparin. We therefore needed to identify the plausible binding site for 24, which might 
explain mechanism and help in the development of future inhibitors. 
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To explore the possible binding sites for 24 an exhaustive docking search involving 8 
sites on a chimera factor XIa model was performed. The search revealed a unique binding site 
within the A3 domain of factor XIa which satisfied the SAR observed experimentally. 
Additionally it was confirmed that the heavy chain of factor XIa is required for optimal 
inhibition by 24, suggesting that a high affinity binding site is located within the apple domains.  
The A3 domain has been known to be a key domain for factor XIa activity towards factor 
IX activation.
137,259
 It has also been suggested that Arg184 within the A3 domain sits within a 
pocket of the catalytic domain within the zymogen, forming hydrogen bond interactions with 
Ser268, Asp488, and Asn566. Upon activation, there is a dramatic change in the catalytic domain 
which could release the Arg184 from this cavity and allow it to interact with factor IX. Thus 
Arg184 acts as a switch that holds factor XI (zymogen) in an inactive conformation in the 
zymogen form. Binding to the proposed binding site of 24 could possibly restrict the movement 
of the catalytic domain and force the enzyme into an inactive conformation wherein the “switch” 
is in the off-position by restoring Arg184 into the cavity of the catalytic domain, thereby shutting 
down the catalytic activity of factor XIa. 
We also demonstrated that binding of 24 to factor XIa would cause a dramatic increase in 
the hydrodynamic volume of the protein, which is indicative of large conformational changes in 
the overall quaternary structure of factor XIa. It is known that the zymogen form of the enzyme 
is proportionately larger in size compared to the activated form,
128
 suggesting that binding of 24 
may convert the enzyme back into a conformationally inactive zymogen-like shape.  
Our current results highlight the fact that there is a site in the A3 domain of factor XIa 
which can be targeted using small aromatic lignin-like molecules with relatively fewer sulfate 
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groups to produce potent, allosteric inhibition of factor XIa. Such allosteric inhibition brings 
about large conformation change within the protein structure possibly reverting the enzyme into 
an inactive zymogen-like conformation. Further structural analysis, mutagenesis studies and 
functional bioassays should be performed to confirm the utility of targeting such a site. 
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Appendix A. Abbreviations 
 
13C Carbon 
1H Proton 
APTT Activated partial thromboplastin time 
BDMS bromo dimethyl sulfonium bromide 
BSA Bovine serum albumin 
CD Catalytic domain 
dEGR-fXIa Dansyl-EGR labeled active site factor XIa 
DHP Dehydropolymer 
f Factor 
fFPR-Thrombin Active site fluorescein labeled thrombin 
GAG Glycosaminoglycan 
GPIbα Platelet glycoprotein Ibα 
HAS Hemostasis Analysis System 
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HBS heparin binding site 
HirP A Tyr63-sulfated hirudin peptide with fluorescein, i.e., [5F]-Hir[54-
65](SO3-), 
HIT Heparin-induced thrombocytopenia 
HLE Human leukocyte elastase 
HMWK High molecular weight kininogen 
LMWH low molecular weight heparin (enoxaparin) 
LRR Leucine rich repeats 
NMR Nuclear Magnetic Resonance 
PAR Protease activated receptor 
PK Pre-kallikrein 
PPE Porcine pancreatic elastase 
PPP platelet poor plasma 
PRP Platelet rich plasma 
PT Prothrombin time 
QAOs Sulfated quinazolin-4(3H)-ones  
RPIP-UPLC-MS Reversed-phase ion-pairing ultraperformance liquid chromatography 
mass spectrometry 
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SbO4L Sulfated β-O4 Lignin 
SEC Size exclusion chromatography 
SPGG Sulfated pentagalloyl glucoside  
SPR Surface plasmon resonance 
SSM Sulfated small molecule 
STRAP Sulfated tyrosine rich anionic peptide 
TBDMS tert-butyl dimethyl silane 
TEG Thromboelastography 
TF Tissue Factor 
TH Thrombin 
TM Thrombomodulin 
tPA Tissue plasminogen activator 
TPST tyrosylprotein sulfotransferase 
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